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RESUMO 
 
Dies1 foi recentemente descrito como um novo gene envolvido na diferenciação de 
embryonic stem cells de ratinho. Aloia et al. demonstraram que a expressão deste gene 
aumenta durante a diferenciação de embryonic stem cells em cardiomiócitos e astrócitos 
e durante a adipogénese e neurogénese. Além do aumento da sua expressão durante a 
diferenciação celular, a supressão deste gene permite a manutenção das embryonic stem 
cells de ratinho num fenótipo indiferenciado. A modificação do programa de diferenciação 
parece ser comprometido devido a alteração da via de sinalização da BMP4 onde a 
proteína codificada pelo gene Dies1 evidencia uma função de coreceptor. Além do 
envolvimento deste gene na diferenciação de embryonic stem cells, resultados 
preliminares realizados no nosso grupo (dados não publicados) revelaram que este gene 
poderá ter um função no programa de transição epitélio-mesênquima e no processo 
reverso. Em particular, o nosso grupo observou que a expressão do Dies1 diminuía 
concomitante com a transdiferenciação da célula epitelial. Nestes dois processos, 
diferenciação das embryonic stem cells e transição epitélio-mesênquima, dois 
mecanismos de regulação da expressão génica têm sido descritos e associados com a 
expressão do Dies1, nomeadamente a regulação por microRNA-125a (miR-125a) e miR-
125b e a metilação do promotor do gene.  
Uma vez que o Dies1 se encontra associado a dois programas de diferenciação celular, 
colocamos a hipótese de que este gene poderia estar envolvido na diferenciação celular, 
não apenas no que diz respeito à diferenciação de embryonic stem cells e na 
transdiferenciação de epitélio para mesênquima, mas também em outros programas de 
diferenciação, como o cancro. Desta forma, o nosso objectivo é estudar o papel do Dies1 
em cancro gástrico e o possível mecanismo de regulação de expressão que pode levar à 
expressão diferencial deste gene.  
Para alcançar este objectivo, a expressão do gene Dies1 e o possível mecanismo de 
regulação foi estudado numa série de linhas celulares de cancro gástrico. Além disso, 
numa série de amostras de cancro gástrico foi também estudada a expressão do gene 
Dies1, assim como a expressão de um marcador epitelial (CDH1) e mesenquimal (CDH2) 
de forma a encontrar associações relevantes entre a expressão destes genes e do gene 
em estudo. 
 
Os nossos resultados revelaram que nas linhas de cancro gástrico o gene Dies1 tem uma 
menor expressão que o estômago normal. No estudo de um possível mecanismo que 
estivesse na origem da diminuição de expressão deste gene, sequenciamos toda a 
 XII 
região codificante do gene Dies1, no entanto nenhuma mutação foi encontrada. Foram 
também estudados outros mecanismos de regulação: a metilação do promotor do gene 
Dies1 e a expressão do miR-125a. Nestes estudos observamos que nas linhas celulares 
GP202 e AGS, a ilha CpG do gene Dies1 encontrava-se parcialmente metilada ou 
hipermetilada. Além destes resultados, as linhas celulares AGS, KATO III e MKN28 
demonstraram uma elevada expressão do miR-125a concomitante com a diminuição dos 
níveis de expressão do Dies1.  Nas restantes 3 linhas celulares de cancro gástrico 
estudadas, nenhuma associação foi encontrada entre a expressão do miR-125a ou o 
estado de metilação do promotor e a expressão do Dies1. Estes resultados sugerem que 
a presença de outros mecanismos regulatórios podem estar na origem da diminuição da 
expressão deste gene.  
Na nossa série de cancro gástrico a expressão do gene Dies1 foi, no geral. aumentada e 
apenas 6 das 25 amostras tumorais apresentaram uma diminuição da expressão do 
Dies1 quando comparado com o respectivo par normal. Estes resultados foram 
inconsistentes com os resultados preliminares. Esta inconsistência pode ser devida ao 
facto de terem sido utilizados diferentes métodos para a normalização da expressão do 
gene (pool de amostras normais vs. amostras normais pareadas). Análises futuras com 
um maior número de casos será necessário para revelar a variação da expressão do 
Dies1 em cancro gástrico. Apesar disso, nós observamos que a expressão do Dies1 
estava aumentada no cancro gástrico com uma positiva correlação com a expressão do 
gene CDH1 (marcador epitelial).  
 
Globalmente, o nosso estudo sugere que o Dies1 encontra-se diferencialmente expresso 
no cancro gástrico e que diferentes mecanismos de regulação podem explicar esta 
diferente expressão. A correlação observada entre a expressão do gene Dies1 e CDH1 
sugere uma associação entre o Dies1 e uma diferenciação epitelial.  
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ABSTRACT 
 
The role of Dies1 gene as a new player in mouse embryonic stem cells differentiation was 
recently discovered. Aloia et al. have shown that Dies1 expression increases during 
differentiation of embryonic stem cells into cardiomyocytes and astrocytes and in mouse 
adipogenesis and neurogenesis. In addition, by supressing Dies1 expression the 
differentiation program is impaired and mouse embryonic stem cells maintain their 
undifferentiated phenotype. The differentiated program seems to be compromised due the 
alteration of BMP4 pathway, where Dies1 protein seems to have a regulatory co-receptor 
function. Additionally to the involvement of Dies1 gene in embryonic stem cells 
differentiation, preliminary results from our group (unpublished data) reveal a possible role 
of this gene in epithelial to mesenchymal transition and mesenchymal to epithelial 
transition programs. In particular, our group has observed that Dies1 expression 
decreased in concomitance with the epithelial cell transdifferentiation. In these two 
processes, embryonic stem cells differentiation and epithelial to mesenchymal transition, 
two different regulatory mechanisms have been described and associated with Dies1 
expression, namely the regulation by microRNA-125a (miR-125a) and miR-125b and 
promoter methylation.  
 
Due the association of Dies1 with two different programs of cellular differentiation we 
hypothesize that this gene may be involved in cell differentiation not only at embryonic 
stem cell level, as well as in epithelial to mesenchymal transdifferentiation and could also 
be relevant in other differentiation programs, such as in cancer. Therefore our main aim 
was to dissect the role of Dies1 in gastric cancer and its possible expression regulatory 
mechanisms that may lead to a differential expression of this gene. 
To achieve this goal, Dies1 expression and possible regulatory mechanisms were studied 
in a set of gastric cancer cell lines. In addition, Dies1 expression was studied in a series of 
gastric cancer samples in concomitance with an epithelial and mesenchymal marker, in 
the search for relevant associations.  
 
Our data has shown in gastric cancer cell lines screened Dies1 was down-regulated when 
compared to normal stomach. In the search for possible mechanisms underlying such 
downregulation, we have sequenced the entire coding locus of Dies1, however no 
mutations were found. Alternative regulatory mechanism assessed were Dies1 promoter 
methylation status and miR-125a expression. We observed that in AGS and GP202 cell 
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lines, Dies1 CpG island was partially methylated or hypermethylated. In addition, AGS, 
KATO III and MKN28 cell lines displayed an elevated expression of miR-125a in 
concomitance with decreased Dies1 expression levels. For the remaining 3 gastric cancer 
cell lines screened, no significant association with miR-125a or promoter methylation 
status were observed, suggesting the presence of others regulatory mechanisms that can 
explain the down-regulation of this gene. 
In our gastric cancer series Dies1 was an overall overexpression, and only 6 out of 25 
tumour samples screened present a down-regulation of Dies1 expression when compared 
to the normal pair. These results were inconsistent with the preliminary results, which can 
be due to different approaches used for gene expression normalization (pool of normal 
samples vs. paired normal samples). Further analyses with a higher number of cases will 
be necessary to reveal the expression variation of Dies1 in gastric cancer. Nevertheless 
we observed that Dies1 expression was increased in gastric cancer with a positive 
correlation with the CDH1 expression levels (epithelial marker).  
 
Overall, our study suggests that Dies1 is differentially expressed in gastric cancer and 
different mechanisms might explain its expression. The correlation observed between 
Dies1 and CDH1 expression suggests an association of Dies1 with epithelial 
differentiation.  
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  3 
GENERAL INTRODUCTION 
 
The following general introduction section concerns the three main subjects studied in this 
thesis. Firstly, we will present the current knowledge on Differentiation of Embryonic Stem 
cell 1 gene and its involvement with embryonic stem cell differentiation. Secondly, we will 
present the general alterations associated with epithelial mesenchymal transition and its 
association with cancer. A brief description of gastric cancer, its molecular features and its 
association with epithelial-mesenchymal transition process is the third issue that will be 
addressed in this chapter. 
 
1. Dies1: a gene involved in cell differentiation 
 
A new player involved in mouse embryonic stem cell (mESC) differentiation was recently 
discovered by Aloia, et al. (2010). This gene was recognized in a short hairpin RNA 
(shRNA) functional screening for genes, whose suppression, resulted in failure of mESCs 
undergoing an in vitro neural differentiation (1). This gene (riken cDNA 4632428N05) was 
named Differentiation of Embryonic Stem cell 1 (Dies1), however is also known as V-
domain Ig suppression of T-cell activation (VISTA), Platelet receptor GI24 precursor 
(GI24), Programmed Death-1 Homolog (PD-1H), Stress-induced secreted protein-1 
(SISP-1) or chromosome 10 open reading frame 54 (C10orf54) (1-4). 
The Dies1 protein sequence is highly conserved in numerous vertebrate species, with 
high similarity between mouse and human (85.6%). In humans, this gene is localized in 
the reverse strand at chromosome 10 (location q22.1), in the following genomic 
coordinates: chr10: 71,747,559-71,773,498. The expected protein encoded by this gene is 
composed by 311 amino acids (aa) in humans (309 aa in murine species) (5). The protein 
sequence predicts a transmembrane protein, with a cytoplasmic region and a hydrophobic 
helix with transmembrane characteristics (1). In the N-terminal region, this protein exhibits 
possible Asn-glycosylation sites, as do many receptor proteins, and a V-type Ig-like 
domain, also present in proteins with adhesion functions such as cadherins. These two 
characteristics support the transmembrane categorization of Dies1 (figure 1) (1). Its 
transmembrane tract is similar to single pass membrane proteins such as Cadherin 6 and 
Neural cell adhesion molecule 1 (NCAM-1), while its cytoplasm domain contains 
numerous possible serine, threonine and tyrosine residues and does not have homologies 
with others proteins (1). By immunocytochemical detection it was possible to confirm the 
transmembrane localization of Dies1 protein (5). 
  4 
 
 
 
 
 
 
Figure 1 – Dies1 membrane protein. A. Amino acid sequence predict from a human Dies1 gene. B. Dies1 
protein predicted domains. Numbers indicates the aa position; SS, signal sequences; TM, transmembrane 
domain. Data provided in Ensemble database C. Immunostaining with a FLAG antibody demostrating the 
plasma membrane localization of Dies1 in mESC. Adapted from Aloia, el al. (1)  
 
The mESCs transfected with shRNA targeting Dies1 result in a decrease of specific 
neuron differentiated markers, even when cultured in a medium without the leukemia 
inhibitory factor (LIF, a factor required to sustain self-renewal of mESC). The suppression 
of Dies1 expression affects not only neural, but also glial differentiation, and cells maintain 
the expression of markers of undifferentiated phenotype, such as Oct4 and Nanog. Dies1 
Knock-down (KD) cells restore the proper differentiation ability after re-expression of 
Dies1 gene (1). 
The differentiation of mESC into cardiomyocytes is also impeded with Dies1 silencing. 
Additionally, in both, neural and cardiac differentiation, Dies1 mRNA expression levels 
increase when cells are cultured in differentiation promoting conditions (1). 
An independent group also confirmed the function of Dies1 using a different differentiation 
program: adipogenesis. In this model the expression of Dies1 transcript increases after 
one day of induction of adipogenic differentiation in 3T3-L1 preadipocytes; the mature 
adipocytes reach the maximum level of this transcript. Similarly to what was described by 
Aloia et al., the suppression of Dies1 leads to partial inhibition of preadipocytes 
differentiation (5). Conversely, Dies1 expression does not have a significant change 
during myogenesis (5). 
The evidences collect by Aloia et al. and Ren et al., lead to the conclusion that Dies1 is an 
important gene for cellular differentiation programs, in particular in cardiac, neural, and 
adipocyte differentiation (1, 5). 
Following the protein structure and function Aloia et al. proved the function of Dies1 as a 
receptor protein. mESCs transfected with mutant Dies1 (encoding only the N-terminal part 
C A 
B 
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of the protein) had similar results to Dies1 suppression results, suggesting that mutant 
Dies1 function as a dominant negative form. However, Aloia et al. also showed that Dies1 
extracellular domain by itself is not able to work as a soluble protein, suggesting that 
Dies1 has a signalling function inside the cell (1). 
Overall, these results indicate that Dies1 functions as a surface receptor, possibly 
interfering with signalling pathways controlling mESC pluripotency (1). 
 
1.1. The role of Dies1 in the BMP4 signalling pathway 
The LIF cytokine is necessary but not sufficient to maintain mESC undifferentiated in cell 
culture. Members of the transforming growth factor-β (TGF-β) family namely, bone 
morphogenetic proteins (BMP) and Nodal/Activin, have been reported to be necessary for 
the maintenance of mESC identity (6-8). In order to preserve the mESC phenotype, Dies1 
possibly interacts with one of these pathways. Indeed, Dies1 KD alters BMP4 signalling 
pathway without directly disturbing LIF and Nodal/Activin pathways (1). Dies1 silencing in 
undifferentiated cells leads to a significant decrease in mRNA expression of BMP4 
effectors, Inhibitors of Differentiation (Ids) 1, 2 and 3, and also a reduction of 
phosphorylated Smad1/5/8 levels. Without directly affecting it, Dies1 KD indirectly 
activates the Nodal/Activin signalling pathway, which reflects an increase expression of 
their downstream genes: cripto, lefty1 and lefty2 (1). 
Bone morphogenetic proteins and Nodal/Activin are members of the TGF-β superfamily of 
cytokines, which are involved in a large variety of functions (9). BMP pathways are mainly 
involved in induction of cartilage and bone formation, cell differentiation, proliferation (10), 
apoptosis (11) and epithelial-mesenchymal transition (12, 13). Nodal/Activin signalling is 
implicated in development events and distinct studies have demonstrated that it is 
essential for embryonic stem cells maintenance (14). The TGF-β superfamily members 
initiate their cellular signalling pathways by binding the ligands to a heterotetrametric 
complex of type I and type II receptors (15). The constitutively active type II receptor 
kinase (TGF-RII, BMPRII, ActRII and ActRIIB) phosphorylates the type I receptor, 
known as activin receptor like kinase (ALK-1 to ALK-7), that enables the recruitment and 
activation of the receptor-regulated Smads (R-Smads): Smad1, Smad2, Smad3, Smad5 
and Smad8 (16). Activin and Nodal receptor type I specifically activates Smad2 and 
Smad3, whereas Smad1, Smad5 and Smad8 transduce signals in the BMP pathway. 
Activated R-Smads form a complex with the common mediator, Smad4, that translocate 
into the nucleus and interacts with various transcription factors to regulate the expression 
of target genes (16, 17). The ligand-dependent phosphorylation of R-Smads is inhibited 
by direct competition for receptor binding by the inhibitory Smads (Smad6 and Smad7) 
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(16). In parallel, the receptor complexes can also trigger diverse non-Smad pathways, 
such ERK, p38 and JUN N-terminal kinase (JNK) MAP kinase (MAPK), RHO-like 
GTPases and Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) (15, 17). 
 
The BMP and Nodal/Activin pathways have a direct relation since they share the Smad4 
cofactor (16, 17). The increased activity of the Nodal/Activin pathway, in Dies1 KD cells, 
seems to be related with Smad4 availability. Indeed, even in the suppression of 
Nodal/Activin pathway activity, Dies1 KD leads to a decrease of Id1 and Id3 mRNA levels, 
indicating that Dies1 acts directly on the BMP4-Smad1/5/8 pathway, and the Nodal/Activin 
pathway is only indirectly activated. 
The interaction between Dies1 and the BMP4 pathway is reinforced by direct interaction of 
Dies1 with BMP4 cytokine, and by co-localization of Dies1 with the only BMP-type I 
receptor expressed in mESC: ALK3 (1, 18). All the evidences thus suggest that Dies1 
plays a role as co-receptor in BMP4 pathway (1, 18). The suppression of Id1 protein, a 
BMP4 pathway target, is not sufficient to keep mESCs in their undifferentiated state. 
Therefore, in order to maintain this state by Dies1 knockdown, Nodal/Activin activity is 
essential (1). 
Dies1 suppression in mESC leads to a maintenance of stemness, and seems to depend 
on the equilibrium between Nodal/Activin and BMP4 signals (1). 
In the adipogenesis model, Dies1 KD leads to a partial impairment of differentiation. 
However, in contrast to what was reported for mESCs, the levels of BMP4-induced 
phospho-Smad1 did not decrease. Also during adipogenesis BMP4 transcript levels have 
an inverse relation with Dies1 levels (5). 
The enrolment of Dies1 in BMP4 signalling differs according to the differentiation model 
studied and needs to be further explored in order to clarify this association. 
 
1.2. MiR-125 involved in Dies1 regulation 
The small non-coding single-stranded ribonucleic acids (~22 nucleotides), microRNA 
(miRNA) family, play an important role in post-transcription regulation of gene expression 
in many biological processes, and aberrant or perturbation of their expression levels have 
an association with different disease, as an example of cancer (19-21). A key determinant 
for miRNA target recognition is based on base pairing of miRNA and the target mRNA. 
Usually, miRNA bind to mRNA in the 3′ untranslated regions (3′-UTRs), and many 
evidences suggest that miRNA do not function as naked RNA and they incorporate into a 
RNA-induced silencing complex also known as microRNA ribonucleoprotein complex 
(miRNP). The gene silencing can be obtained at 3 stages that include pretranslational, 
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cotranslational, and posttranslational steps and exert direct and indirect effects on 
translation machinery. MiRNA can mediate gene repression by deadenylation and decay 
of target mRNAs and repression of translation initiation that lead to degradation or storage 
of mRNA; or repress of protein expression by elongation block or photolytic cleavage of 
emerging polypeptides (21-23). 
By crossing the nucleotide sequence of the 3’UTR Dies1 mRNA with a list of miRNA 
previous found in ESCs (24), it was identified a possible binding site for miRNA-125a and 
125b. 
These two miRNAs belongs to the miR-125 family, which is highly conserved among 
mammals, is transcribed from 3 different clusters and composed by 3 homologs: hsa-miR-
125a, hsa-miR-125b-1 and hsa-miR-125b-2 (25, 26). The members of this family play a 
role in many different cellular processes like cell differentiation, proliferation and apoptosis 
(25). MiR-125a was already described to play a role in ESC differentiation, by repress a 
considerable master regulator controller the pluripotency of ESC, LIN28 (27), and by 
directly bind to the 3’UTR of Smad4, in a non conserved region between human and 
murine specimens, and promote human ESC entry into the neural lineage (28). 
The study of miR-125 as a possible regulator of Dies1 expression was performed by 
Parisi, et al. The overexpression of both pre-miR-125a and 125b result in a decrease of 
Dies1 protein levels while the suppression of these 2 miRNAs resulted in the 
accumulation of Dies1 protein, without affecting the mRNA levels (18). 
MiR-125a and miR-125b are differentially expressed in undifferentiated mESCs. Whereas 
the former is expressed in mESCs, the latter is almost undetectable and its expression 
increases during the first steps of differentiation (18, 29). MiR-125a was studied in mESC 
differentiation, and its overexpression recapitulates the effect of Dies1 suppression, with 
the persistence of stemness characteristics and a decrease of Id1 and Id3 expression. 
(18). Moreover the co-transfection of pre-miR-125a with a vector containing Dies1 lacking 
the 3’UTR, resulted in a normal differentiation with normal Ids levels. All this evidence 
indicates that, the effect of miR-125a overexpression in mESC pluripotency is mostly 
mediate by Dies1 (18). 
The induction of BMP4 signalling pathway increases the levels of miR-125a and Dies1 
protein, which in turn is markedly decreased after 24h of BMP4 treatment. This finding, 
together with the evidences that Smad1 interacts with miR-125a promoter region, 
suggests the existence of a negative feedback loop, where BMP4 controls Dies1 level 
through direct recruitment of Smad1 to the promoter of miR-125a gene (figure 2) (18). 
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Figure 2 – Schematic representation of regulatory loop mediated by miR-125a. The treatment with BMP4 
leads to an overexpression of miR-125a and down-regulates the Dies1 levels and decrease the BMP4 signal. 
Adapted from Parisi, el al. (18)  
 
Through this regulatory loop mechanism BMP4 can modulate the sensitivity of the cells to 
itself. This can be important for mESC transition to epiblast stem cell (epiSC), that is block 
by BMP4 signalling (30). Indeed the overexpression of miR-125a that leads to Dies1 
suppression and down-regulation of BMP4 signalling, resulting in ESC differentiation to 
epiSC (18). However the progression of the differentiation program appears to be slower 
and cells retain an epiSC phenotype while the levels of miR-125a remained elevated. This 
was concomitant to the overexpression of Nodal/Activin pathway that is known to be 
necessary to maintain the pluripotent state of mouse epiSCs (18). 
Besides the low levels of miR-125b in ESCs, its expression increases during the first 
steps of differentiation. The study of this miRNA in ESC differentiation reveals that the 
overexpression of this miRNA blocks cells differentiation at epiblast stage and a large 
fraction of these cells maintain the pluripotent state (29). Also the Dies1 re-expression is 
able to fully rescue the block at the epiblast stage induced by miR-125b. Similar to miR-
125a, miR-125b overexpression induced a significant decrease of BMP4 targets, and an 
increase of Nodal/Activin targets. However, contrary to miR-125a, miR-125b is not directly 
regulated neither by BMP4 neither by Nodal/Activin pathways, and the mechanism that 
regulate miR-125b remains unknown (29). 
Until now, as far as we know, the regulation of Dies1 by overexpression of miR-125 is the 
only regulatory mechanism described in literature. 
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1.3. Dies1 in a non-differentiation context 
Besides embryonic differentiation, others functions have been assigned to Dies1. A single 
report demonstrates that Dies1 protein serves as a substrate and a positive regulator of 
membrane-type1 matrix metalloproteases (MT1-MMP). The authors suggest that this 
protein also contributes to the invasive growth of HT1080 cells by up-regulation of the cell-
surface MT1-MMP (3). 
In 2011, Li Wang, demonstrated that the Dies1 protein, termed as VISTA in this report, 
exerts immunosuppressive activities on T cells. VISTA expression on antigen presenting 
cells directly suppresses T cell proliferation and cytokine production, and authors 
hypothesize that VISTA is an inhibitory ligand that down-regulates T cell-mediated 
immune responses (2). A recent study, in a mouse model, indicates that VISTA is highly 
expressed on tumour-infiltrating myeloid cells, and the monotherapy with VISTA 
monoclonal antibody (mAb) impairs the tumour growth in a bladder and melanoma tumour 
mouse models. VISTA blockage enhanced tumour-specific T-cell response, and increased 
the immune-stimulatory phenotype of dendritic cells (31). However another study 
described that an antibody to Dies1 protein, herein denoted PD-1H, is capable of 
modulating allogeneic T cell responses accompanied by inhibition of T cell accumulation 
and expansion in graft-versus-host disease in a mouse model (4). This study suggests, 
contrarily to previous, that PD-1H has a stimulatory role on T cell (4). 
Further studies are, therefore, required in order to elucidate the function of this protein in 
both immunological and non-immunological context. 
 
 
In summary, the relevance of Dies1 in ESC differentiation has been demonstrated 
by several authors. Besides the involvement in ESC differentiation program, a 
preliminary study performed in our group has shown that Dies1 may have a role in 
other differentiation/transdifferentiation programs, namely epithelial mesenchymal 
transition and the reversed process.  
 
 
 
 
 
 
 
  10 
2. Epithelial Mesenchymal Transition and Mesenchymal Epithelial Transition 
 
Epithelial and mesenchymal cells are one of the most primitive divergence cell 
phenotypes in early organisms (32). However, even in cells within a terminally 
differentiated state, these two phenotypes are not static and can be highly plastic and 
dynamic (32-34). 
Epithelial to Mesenchymal Transition (EMT) is a complex process that enables the 
transdifferentiation (first cells de-differentiates and afterwards, cell differentiate into the 
new lineage) of epithelial cells to acquire an invasive and motile mesenchymal phenotype. 
Mesenchymal to Epithelial Transition (MET) is the reverse process (33, 35-38). EMT/MET 
represents a highly conserved biological process that normally occurs during 
development, wound healing, and regeneration, and has also been increasingly 
recognized in pathology, namely in fibrosis and cancer metastasis (33, 35, 36). 
The EMT program allows the epithelial cells to loose the apical-basal polarity by 
dissolutions of cell-cell junctions, such as: tight junctions that is accompanied by decrease 
of claudin, occluding and zonula occludens (ZO) expression; loss the expression of 
adherent junction, epithelial cadherin (E-cadherin) that leading to nuclear accumulation of 
β-catenin and p120 catenin; disruption of desmosomes and; compromise the integrity of 
gap junctions. This process is also characterized by cytoskeletal architecture remodelling 
with formation of actin stress fibers and expression of mesenchymal cytoskeletal proteins 
such vimentin and reorganization of extracellular matrix (ECM) by up-regulating the 
expression of extracellular protein such fibronectin and collagens, proteases and others 
remodelling enzymes (39-41). Down-regulation of epithelial markers as E-cadherin, 
epithelial cytokeratins, occludins and claudins are accompanied by the increase 
expression of new mesenchymal markers, like N-cadherin, vimentin, fibronectin and α-
smooth muscle actin (40, 41). All these alterations allow cells to acquire spindle shape 
morphology with cell protrusions and increased cell motility. Furthermore, cells develop 
resistance to senescence and apoptosis (32, 39, 42). 
A high diversity of extracellular signals can trigger the EMT program, including soluble 
growth factors, such as TGF-β and epidermal growth factor (EGF), components of 
extracellular matrix, such as collagen and hyaluronic acid, and hypoxia (34, 41). In 
response to these signals, diverse signalling pathways active intracellular effector 
molecules, as example of small GTPase family (Ras, Rho and Rac) and members of the 
Src tyrosine-kinase family that are involved in disrupt of junction complexes and 
cytoskeletal organization. Several transcription factors, such as Snail1, Snail2, Zeb1, 
Zeb2, and Twist1 involved in either repression of epithelial or activation of mesenchymal 
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genes, are also activated during EMT (34, 39, 40). 
 
2.1. E-cadherin expression alteration and “cadherin switch”: the hallmarks of 
EMT/MET 
Among many changes in gene expression, alterations on proteins functions in cell-cell 
and cell-matrix adhesion have a central role during EMT/MET. E-cadherin protein 
mediates epithelial cell-cell adhesion, and a decrease or loss of its expression constitute a 
well establish hallmark in EMT. E-cadherin down-regulation and/or dysfunction are found 
in all types of EMT in order to reinforce the destabilization of adherent’s junctions (39, 43). 
In cancer the loss or abnormal expression of E-cadherin plays an important role as an 
invasion suppressor gene and are associated with tumour progression, metastasis and 
poorer prognosis in a variety of epithelial carcinomas, such as, gastric, breast, 
hepatocellular and colorectal carcinomas (44, 45). 
E-cadherin is a member of the classical/type I cadherin family of cadherin superfamily, 
that count with 4 more members: placental (P)-, neural (N)- retinal (R)- and muscle (M)-
cadherin (46). Classical cadherin family members have single-pass transmembrane 
glycoprotein that interact in a calcium dependent manner and establish a homophilic 
protein-protein interaction with cadherin molecules on the neighbouring cells (47-49). The 
intracellular domain of E-cadherin, interacts with some catenin proteins, β-, α-, γ-catenins 
to form a cytoplasmic cell-adhesion complex that links to the actin cytoskeleton through α-
catenin and stabilize the cadherin-catenin complex (48, 50). Another catenin family 
member, p120-catenin, interacts with E-cadherin at its juxtamembrane domain and, not 
only stabilizes E-cadherin at cell membrane, but also prevents the protein from lysosome 
degradation. p120-catenin also interacts with the RhoA, Rac and Cdc42 (members of Rho 
GTPase), all key regulators of actin cytoskeleton organization (47, 49). Besides the 
adhesion function, E-cadherin is also involved in signalling, mostly by protein interaction 
with its cellular domain or by inhibition the ligand activation of receptors tyrosine kinase, 
such epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 
(HER2), the insulin-like growth factor 1 receptor (IGF-1R), and the hepatocyte growth 
factor receptor (HGFR). (47). 
E-cadherin is an important hallmark of the EMT process, but how the loss of E-cadherin 
promote EMT and tumour invasion? (1) First, down-regulation of E-cadherin lead to a 
mechanical disrupt of adhesion junctions with loss of contacts among the neighbouring 
cells, leading to the detachment of malignant cells from the epithelial-cell layer (46, 48); 
(2) Second, cells become more responsive to tumour cell migration and tumour growth by 
several growth factors, such EGF, once cells lose the negative regulation provided by E-
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cadherin (46, 48); (3) The disruption of E-cadherin cell-cell contact release proteins from 
the cell adhesion complex. These proteins have different functions depending on their 
cellular localization and with the loss of adhesion complex they become accessible to 
participate in alternative signalling pathways (43). One example is β-catenin, when it is 
released for cytoplasm, is stabilized by active Wnt signalling or by mutation in the β-
catenin phosphorylation/degradation pathway, which allows its relocation to the nucleus, 
where it may activate the expression of Tcf/LEF complex. This complex modulates the 
expression of a large number of genes involved in cell proliferation, migration, invasion 
and morphogenesis, such c-myc, cyclin D1 and matrix metalloproteases (MMPs). Another 
example is the accumulation of p120-catenin in cytoplasm that is responsible for 
remodelling the actin filaments (33, 35, 43, 47); (4) As mentioned before, the suppression 
of epithelial markers is counterbalanced by increased expression of mesenchymal 
proteins. Specifically, E-cadherin down-regulation is balanced by increased expression of 
the mesenchymal cell-cell adhesion molecule, N-cadherin, that results in a cadherin 
switch with changes in cell adhesion (39, 51). N-cadherin is normally expressed in non-
epithelial tissues, such nervous tissue, vascular endothelial cells, skeletal and cardiac 
muscle cells and is known as a mesenchymal cadherin (46, 47). E- and N-cadherin 
belong to the same cadherin family, and despite their structural and functional similarities, 
these 2 cadherins have different functions (46). In EMT the cadherin switch leads to an 
increase in the motility and invasion capability of cancer cells, and have been related with 
poor prognosis in multiple of cancers, such breast, prostate and pancreatic cancer (51). 
As a classical cadherin, N-cadherin has a homophilic binding pattern, and its expression 
lead epithelial cells to establish contacts with stromal and endothelial cells that normally 
express this cadherin. These contacts contribute to invasion and metastatic dissemination 
of cancer cells (46). N-cadherin also stimulates some signalling pathways that contribute 
to cell metastasis, by facility the binding of fibroblast growth factor 2 (FGF2) to its receptor 
and prevent the receptor internalization that sustain MAPK and PI3K/AKT signalling, 
leading to an increase of cell motility, invasion and segregation of extracellular proteases 
(48). N-cadherin might also activate platelet-derived growth factor (PDGF) receptor 
through association with a small protein called Na+/H+ exchanger regulatory factor 
(NHERF)-2, and induces actin reorganization and cell proliferation (47, 51). 
The disruption of normal E-cadherin function and the switch to the expression of a 
mesenchymal cadherin involve many essentials changes that allows cell to undergo an 
EMT process and contribute for cell motility. 
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2.2. Role of epithelial mesenchymal transition in cancer 
Contemplating the diversity of biological contexts in which EMT is involved, this process 
was classified into 3 different subtypes: the type 1 EMT is associated with embryonic 
implantation and development, such neural crest and fusion of the palate. Many cases of 
this subtype undergo MET to originate a secondary epithelia (42, 52); type 2 EMT is 
involved in wound healing, tissue-regeneration, inflammation, and organ fibrosis. The 
dedifferentiation and transdifferentiation of cells is generated to reconstruct tissues 
following trauma and inflammatory injury. In these case the process is induced in 
response to an inflammation, however when the inflammation insult is not attenuated the 
EMT process can contribute to organ destruction (42, 52, 53). The type 3 EMT occurs in 
carcinoma cells, however the involvement of EMT in cancer in not yet fully accepted 
across the scientific community (33, 54). 
Since the report of Hanahan and Weinberg in 2000, metastases are recognized as one 
fundamental principle of the malignant transformation (55). This progress involves a series 
of sequential steps that culminate in establishment of tumour cells in distant organs. 
Initially cells must detach from primary tumour, became motile, degrade the basement 
membrane and ECM to invade the nearby tissue (invasion) and intravasate into circulatory 
system (intravasion). In circulation only a low number of cells can evade the immune 
system (systemic transport), extravasate through the capillary endothelium into the 
parenchyma of distant organs (extravasation) and proliferate to form a secondary tumour 
(colonization) (33, 56). Besides the existence of multiple models and patterns of invasion, 
mesenchymal single cell invasion has been highly accepted as a mechanism for cancer 
cell metastases, and many in vitro and in vivo, mainly mouse models demonstrate the 
importance of EMT in tumour progression (57, 58). The direct identification of EMT 
process in clinical specimens remains difficult, which leads to a scepticism to accept its 
pathological relevance. This difficulty is mainly due the existence of intermediate states of 
EMT, where a cell can acquire some mesenchymal characteristics, while maintaining 
some epithelial features; also because EMT is often  	   

  (56, 59, 60). Additionally, 
the fact that the EMT is a reversible program feeds the scepticism point of view (61). 
 
The analysis of clinical samples reveals an increase expression of EMT markers in cancer 
cells on the invasive front of aggressive tumours. Also circulating cells from peripheral 
blood of breast cancer patients present an EMT phenotype and many tumour carcinomas, 
such colorectal cancer, the lost of E-cadherin expression are associated with 
undifferentiation cells (62-65). Beside these evidences of EMT process most of the 
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metastatic tumours present an epithelial phenotype, without any spindle morphology and 
with lack of EMT markers (62-65). This suggests that the EMT program is a dynamic 
process and the identification of cells with EMT characteristics may not be successfully 
achieved due the spatial and temporal heterogeneity of EMT in human cancer (56, 59). 
Jean Paul Thiery in 2002 (66) proposed a reversible EMT model, where primary tumour 
cells activate the EMT program, invade and disseminate, and after extravasion to a 
different organ, the cell reverts back to an epithelial phenotype by MET in order to 
facilitate colonization (56, 59). Supporting the sequential EMT/MET model, dynamic 
expression of E-cadherin has been documented in cancer progression, and multiples 
studies, using a mouse models, have demonstrated that tumour cells need to re-acquire 
an epithelial phenotype to form metastatic colonies (58, 67, 68). Tsai and colleagues 
demonstrated, using a mouse model study that a spatiotemporal regulation of EMT is 
essential for the success of metastasis to establish (58). Consistent with this work, Ocaña 
et al. demonstrated that the down-regulation of Prrx1 transcription factor, an EMT marker 
was associated to effective lung metastasis colonization (68). 
All of these evidences are consistent with the role of the EMT/MET process in cancer. The 
transdifferentiation of cells from epithelial to mesenchymal cell type clearly illustrates the 
cell plasticity in EMT/MET program. Besides the cell transdifferentiation, some studies 
reported the association of this process with acquisition of stem cell-like characteristics 
(cell dedifferentiation), both by detecting expression of EMT features in CD44+/CD24-/low 
cells purified from normal and malignant breast cancer tissue, and also by detecting 
increase of expression of cancer stem markers after induction of the EMT program, in 
different human cancer models (33, 69). Also the analyses of tumour tissue, such in 
claudin-low subtype of breast cancer, there was identified a correlation between gene 
expression signatures for both EMT and stem cells (70, 71). 
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3. Gastric cancer 
 
Gastric cancer is the sixth most common cancer worldwide, and is responsible for about 
9% of all cancer-related deaths. The incidence increases with the age reaching a pick in 
patients with 60-80 years and affecting more frequently the masculine sex (ratio: 2:1). 
Although the incidence of gastric cancer gradually decreased over the past 50 years, due 
mainly to reduction of chronic Helicobacter pylori (H. Pylori) infection, gastric cancer is still 
associated with poor prognosis, mainly in western countries (GLOBOCAN 2012) (72). The 
combination of late diagnosis and the lack of efficient treatment options in late stage 
disease lead to a low overall 5-years survival (about 25%). Survival increases to 
approximate 70% in Japan since this country presents a screening programme that allows 
the diagnosis at earlier stages of disease (73). The treatment of this cancer with curative 
proposes it's only possible by surgery and in the early stages; at advances stages regular 
chemotherapy is the standard treatment (73, 74). 
The majority of gastric cancer (≈ 90%) appears in a sporadic setting, while the remaining 
10% of the cases show familial clustering, and only 1-3% of these cases have a defined 
hereditary cause (73). 
 
3.1. Gastric Cancer histological features and pathogenesis 
Most of gastric cancer cases (≈ 90%) are gastric adenocarcinomas, an epithelial 
neoplasm, which displays high morphological heterogeneity (73, 75). This heterogeneity 
reflects the high diversity of different classification systems that has been proposed, such 
as Lauren, Ming, Carneiro, the World Health Organization (WHO) and the Japanese 
classification (76, 77). 
Lauren classification is the most commonly used, this classification in based on tumour 
architectural and cytological features and individualises the tumours in two main types: 
intestinal and diffuse (78). All adenocarcinomas with predominant glandular epithelium, 
cells with intestinal columnar features and good cellular cohesion belong to the intestinal 
type (76, 77). By contrast, individual poor cohesive or small clusters of cells with little or 
no glands formation compose the diffuse type. These cells may contain mucus, which 
gives them a characteristic signet ring appearance (76, 77). In diffuse type usually exists 
an extensive newly formed stroma that difficult the identification of tumour cells by a 
routine coloration (76, 77). Broadly speaking, Lauren’s diffuse type corresponds to an 
undifferentiated type, and the intestinal comprises the differentiated tumours. These two 
groups have different clinicopathological characteristics, distinct epidemiological settings 
and molecular pathogenesis. Intestinal type affects older patients, seems to have a 
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background of chronic gastritis and a high incidence of blood vessel invasion (76, 77). The 
diffuse type of gastric cancer affects patients earlier with a worse prognosis than intestinal 
type, the cells spread more commonly via the lymphatic system to pleura and peritoneum 
(76, 77). 
Gastric cancer is thought to be the result of a combination of environmental factors such 
H. Pylori and Epstein-Barr vírus (EBV) infection, diet, and the accumulation of genetic 
alterations. The histological intestinal type, has been related with a multistep process in 
gastric carcinogenesis postulated by Correa et al., and based on epidemiological, 
pathological and clinical observation (79). The Correa’s multi-stage cascade of gastric 
oncogenesis propose that, adenocarcinoma of intestinal type is the final stage of a serial 
of histological changes triggered by a long inflammatory process and followed by non-
atrophic gastritis, multifocal atrophic gastritis, intestinal metaplasia and dysplasia (80). In 
contrast the development of gastric cancer diffuse type doesn’t seems to follow this 
sequence of events and its pathogenesis remains unclear (76). 
Additional to the intestinal and diffuse type, a third type was included latter in this 
histological classification in order to describe the carcinomas with uncommon or mixed 
histological features (figure 3) (76, 81). 
Apart the morphological classifications others have been proposed based on mucin 
staining and tumour location and clinical course (82, 83). 
 
 
Figure 3 – Gastric adenocarcinoma histological subtypes. A. The intestinal subtype has a glandular 
architectural feature whereas B. a poor cohesive tumour cells are the main characteristic of the diffuse 
subtype. C. Additional to the major 2 subtypes the mixed subtype include an intestinal and diffuse histological 
features.   
 
 
 
 
A B C 
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3.2. Gastric cancer under a molecular point of view 
Together with the histological heterogenetic, also at biological level, gastric cancer is 
highly heterogeneous. Many efforts have been done to understand gastric cancer at the 
molecular level to complement traditional histopathological diagnosis, prognosis prediction 
and also to find new molecular alterations to be used in targeted therapy (84-86). Gastric 
cancer, as all cancers, is a chronic “proliferative” disease with multiple abnormalities that 
disturb a high variety of cellular functions, such cell cycle regulation and apoptosis (e.g. 
cyclin E, cyclin D1, TP53), DNA repair (e.g. MLH1, MSH6, BAX), chromatin remodeling 
(e.g. ARID1A and MLL3), cell adhesion (e.g. CHD1, FAT4, RHOA), invasion and 
angiogenesis (e.g. VEGF) and signalling pathways (e.g. Wnt, mTOR, TGF-β) (73, 77, 87, 
88). All these abnormalities are due to changes in various oncogenes and tumour 
suppressor genes (TSG) and can be the result of multiple genetic alterations: point 
mutation, recombination, amplification, and/or deletion. Beside the genetic alterations, 
non-genetic changes such miRNA gene regulation and DNA methylation, have an 
important role in gastric cancer carcinogenesis (87, 89). 
 
Gene amplification is one of the main alterations that drive carcinogenesis. The two 
growth factor receptors: EGFR (encoded by EGFR) and HER2 (encoded by HER2) are 
two members of the EGF receptor family altered in gastric cancer (87, 90, 91). HER2 
amplification has been reported in 6-32% of gastric cancer, mostly associated with 
intestinal type and, despite the controversy, seems to be associated with poor prognosis 
and tumour aggressiveness (92-94). Regardless the discrepant prognosis results and due 
the lack of treatment options for advanced stages of gastric cancer, U.S. Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) approved transtuzumab (in 
combination with chemotherapy) as a treatment option for patients with HER2-positive 
metastatic gastric cancer (94). Similarly to HER2 also EGFR amplification are present in 
this cancer and associated to lymph node metastasis, advanced tumour stage and poor 
survival (91). Additionally, FGFR2 and MET (encode HGFR), which encodes receptors 
tyrosine kinases, and KRAS (encodes a membrane bound small GTPase protein) are also 
amplified in gastric cancer (95), Niantao Deng and co-workers, in a recent report using 
high-resolution single nucleotide polymorphism arrays, demonstrated that amplification of 
KRAS, HER2, EGFR, FGFR2, and MET present in 37% of gastric cancer patients are 
mutually exclusive to one another, and the possibility to apply a receptor tyrosine 
kinase/KRAS-directed therapy can constitute a good therapeutic approach (96, 97). 
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In addition to gene amplification, oncogenic mutations occurs in gastric cancer, examples 
of this is the activated mutations in PI3K catalytic subunit alpha and KRAS, that is a rare 
event in this cancer compared with amplification of this gene (73, 88, 89, 98). 
Beside oncogene activation, a high number of TSG have been reported in gastric cancer 
pathogenesis, TP53, RUNX3 and CDH1 are three of these examples (99). 
p53 (encoded by TP53), a nuclear protein involved in cell cycle, is the most studied TSG 
in cancer (100). The TP53 is frequently inactivated in gastric cancer by missense 
mutations, which represent the higher mutations rate in this cancer, and by loss of 
heterozygosity (LOH). TP53 mutations are not tumour specific and have been identified in 
pre-malignant lesions, also its alterations are not differently expressed in both histological 
types, and the prognostic impact of p53 alterations is still controversial (100). 
RUNX3 (Runt-related transcription factor3, encoded by RUNX3) is a well establish tumour 
suppressor in gastric cancer that has an antiproliferative and apoptotic effects. 
Additionally, Voon, et al. and Peng Z and co-workers demonstrated, using animal models, 
an inversely association with loss or decrease in RUNX3 expression and increased of 
VEGF expression, elevated microvessel formation and EMT induction in gastric cancer 
cells (101-103). A reduction of RUNX3 transcription factor activity is due homozygous 
deletion, hypermethylation on promoter region, or protein mislocalization (103, 104). 
The CDH1 gene encoding homophilic cell-cell adhesion protein, E-cadherin, that has a 
pivotal function in maintain cell polarity and epithelial architecture (50). Alteration in its 
function has a role in tumour development and invasion and CDH1 has been accepting as 
a TSG in gastric cancer (50, 105). About 90% of gastric cancer lose or have an aberrant 
E-cadherin expression, triggered by diverse mechanisms (50, 106, 107). Corso et al., 
studied the E-cadherin alterations in a gastric cancer cohort, and reported that somatic 
alterations occur in 30% of all gastric cancer cases (n= 246), 20% with promoter 
hypermethylation, and 10% with structural alterations (somatic mutations and LOH). 
However, more than 50% of patients with altered E-cadherin expression were negative for 
the alterations studied (108). Others alterations may have been present, such for example 
the deregulation of E-cadherin expression by miRNA such miR-101 and miR-200 family 
members and transcription factors repressors, aberrant glycosylation and proteolytic 
cleavage by MMP (50, 106, 107). In Corso et al. study, patients with CDH1 structural 
alterations had a significant poorer survival rates than all others patients, and epigenetics 
alterations were more often present in diffuse histological type and associated with lymph 
node metastasis (108). 
Regardless the CDH1 specific alteration, deregulation of E-cadherin expression is often 
associated with cellular dedifferentiation, its expression reduction was associated with 
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poor overall survival, and decreases tumour cell sensitivity to conventional and targeted 
therapies (109-112). 
E-cadherin can function as a biomarker in gastric cancer, and the CDH1 inactivating 
mechanism may deliver information about the progression, invasion pattern, protein 
expression, and may even help predicting therapy response (91). 
 
Apart to alteration in important cancer-associated gene, the loss of genomic stability is an 
important molecular step in gastric carcinogenesis, and creates a great environment for 
accumulation of other genetic and epigenetic alterations, either in tumour suppressor 
genes or in oncogenes (113). The loss of genomic stability has been identified in two 
phenotypes: (1) chromosomal instability, this is the most common genomic instability 
observed in solid carcinomas. These alterations are characterized by loss or gain of whole 
chromosome (aneuploidy) and/or factions of chromosomes (LOH, amplifications and 
translocations), and can lead to oncogene activation or TSG inactivation (113). Belien, el 
al., related that 80% of 221 tumour cases were classified as DNA aneuploid, and were 
associated with the intestinal type and presence of metastasis (114). (2) The second 
phenotype of genomic instability is microsatellite instability (MSI), defined as length 
change in repeating sequences of 1-6 base pairs of DNA (microsatellites) due to impaired 
of the DNA mismatch repair system. In many cases, MSI occurs due the hypermethylation 
of MLH1 promoter. The frequency of MSI in gastric cancer is 15-20% of sporadic gastric 
cancer (depends on the series), and seems to be associated with older and female 
patients (113, 115, 116). 
 
3.2.1. Molecular classification of Gastric Cancer 
Many efforts have been done to achieve a molecular classification that can subdivide 
gastric cancer in different groups according to a biological profile. 
Recently, Lei, et al., based on gene expression profiling of 248 gastric tumours, distributed 
gastric tumours into three subtypes, according to their biological characteristics and 
named them as: mesenchymal, proliferative and metabolic (85). 
The proliferative type was characterized by a specific signature of genes related to the cell 
cycle and DNA replication with high activities for several oncogenic pathways: E2F, MYC, 
and RAS. These tumour present histological characteristics of intestinal type, at molecular 
level they are characterized by frequent TP53 mutations and copy number alterations. 
The second subtype of gastric cancer, metabolic subtype, showed a gastric phenotype, 
with high activity of pathways related to spasmolytic-polypeptide-expressing metaplasia 
(SPEM), an intermediate step in the Correa’s multi-stage cascade of gastric oncogenesis 
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(79). Concerning treatment, this was the only sub-type for which patients benefited from 5-
fluorouracil chemotherapy with better cancer-specific and disease-free survival (85). 
Mesenchymal type, as the name suggests, had mesenchymal characteristic that resemble 
the EMT process: association with the Lauren’s diffuse type, gene alterations are related 
with focal adhesion and extracellular matrix-receptor interaction and has some cancer 
stem cells (CSC) like proprieties. Additionally, cancer cells had high levels of CDH2 and 
low levels of CDH1, similar to the classical “cadherin switch” in EMT (51). This subtype is 
also associated with TGF-β, vascular endothelial growth factor (VEGF), nuclear factor κ-
light-chain-enhancer of activated B cells (NFκB), mammalian target of rapamycin (mTOR), 
and sonic hedgehod (SHH) pathways and showed higher proportion of aberrantly 
hypermethylated CpGs sites. Cell lines from mesenchymal subtype were more sensitive 
to phosphatidylinositor 3-kinase (PIK3)-AKT-mTOR pathway inhibitors, and these 
pathways have also been associated with EMT (39, 85). 
 
3.3. Role of EMT in Gastric Cancer 
The role of EMT in cancer is not yet completing accepted. Many in vitro and animal 
studies have supported that this process occur in cancer cells, however the relevance of 
EMT in human cancer is yet an open question in scientific community. 
Besides the in vitro studies, clinical studies demonstrate that some cancer tissues display 
a dedifferentiation at invasive front regions, where cells lose their polarity and cell-cell 
contacts, leading to single cell detachment (117, 118). These alterations are associated 
with a switch in expression of some epithelial markers to mesenchymal markers in cancer 
cells, supporting an association with the EMT process (117, 118). 
In several studies in gastric cancer, the EMT process seems to be related with tumour 
progression to metastasis. Iwatsuki, el al found that vimentin positive and E-cadherin 
negative cells invading the intratumoral vessels, and Yutaka et al. associated the 
expression of S100A4 protein (considered an mesenchymal marker) with lymph node 
metastasis and peritoneal dissemination. Also, node metastasis were associated with 
undifferentiated cells and reduced of E-cadherin expression (119, 120). These studies 
suggest that cells undergo a mesenchymal differentiation to invade and metastasize (119, 
120). Others groups focus their studies on transcriptions factors associated with EMT and 
metastasis. Ru, et al., associated positive expression of Twist with depth of invasion and 
lymph node and distant metastasis (62). Also Snail1 and Zeb1 have been associated with 
metastasis and invasion in gastric cancer (121, 122). Using a tissue array methodology, 
Kim et al., performed an immunohistochemistry study with epithelial (E-cadherin, 
cytokeratin, β-catenin and γ-catenin) and mesenchymal markers (vimentin, N-cadherin, 
  21 
MMP2, Snail1 and S100A4). After dividing the expression of these proteins in three 
groups according to number of proteins lost or gained in comparison to normal mucosa, a 
group with 4 or more protein changes was associated with poorly differentiated histology, 
advanced tumour invasion, lymph node metastasis and distant metastasis. Also, a 
multivariate analysis indicates that higher EMT-related protein changes were an 
independent prognostic indicator in cancer (123). With the same approach Ryu et al., 
indicated that the combination of epithelial and mesenchymal markers (Snail1, vimentin, 
E-cadherin and CD44) shows a significant association for determining prognosis for 
gastric cancer (124). 
These two studies suggest that the combination of multiple markers expression more 
accurately predict patient outcomes compared with a single marker expression. 
Besides the presence of mesenchymal proteins and the decrease of epithelial markers 
expression, some studies suggest the existence of cancer stem cells-like features 
associated with EMT markers, however few specific markers exists associated with these 
cells in gastric cancer, which turns their detection in tumour samples difficult (124, 125). 
Additional studies based only in protein expression, demonstrate the presence of EMT in 
gastric cancer, an example is the recent study performed by Lei, et al. (described above) 
(85). 
 
Many of these studies demonstrate that gastric cancer is a highly heterogeneous tumour 
type, not only at the cellular but also at the molecular level. As many epithelial neoplasms, 
this heterogeneity is frequently accompanied by the loss of cell differentiation and also 
some studies show that gastric cancer cells can additionally suffer a dedifferentiation and 
transdifferentiation program (EMT) to enhance their ability to metastasise. 
The continuous search for new biomarkers to better characterize this cancer is essential 
to understand the cancer cell biology, which may help on the development of new 
diagnosis and treatment approaches, and also be useful for prediction of prognosis and 
treatment response. 
The Dies1 gene, recently described in a differentiation and transdifferentiation context can 
also be involved in cancer, since many cancer cells lose their differentiation, and can 
suffer a transdifferentiation through EMT process. The study of the involvement of this 
gene in a cancer model, gastric cancer, constitutes the major aim of this thesis. 
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RATIONAL AND AIMS 
 
Dies1 has been associated with differentiation contexts, not only in ESC differentiation, 
but also in EMT/MET, a process characterized by transdifferentiation of epithelial cells. In 
mESC, Dies1 expression increase during neuronal and adipogenesis differentiation 
programs and its suppression maintains cell in an undifferentiation state. During the 
EMT/MET program, Dies1 seems to follow a classical epithelial behaviour, with the 
decrease of its expression, when cells acquire a mesenchymal phenotype, and an 
increased expression at same time that the cell re-acquires the epithelial characteristics. 
Similar to what occurs in ESC differentiation and in an in vitro EMT/MET process, we 
hypothesized that the loss of epithelial cancer cell differentiation may be 
accompanied by alterations of Dies1 expression. 
Gastric carcinoma is one of the examples where cancer cells lose their epithelial features 
by disrupting the normal E-cadherin expression, and sometimes by gaining mesenchymal-
like features. Besides these characteristics, preliminary data suggests that Dies1 gene 
can be differently expressed in this cancer model. 
 
The main aim of this study was to dissect the role of Dies1 in gastric cancer and its 
possible expression regulatory mechanisms. To achieve this goal, 2 specific 
objectives were outlined: 
 
1. Characterize the Dies1 expression in gastric cancer cell lines and tumour samples, 
and explore the possible expression regulatory mechanisms of this gene; 
2. Analyse the expression relationship of Dies1 with an epithelial (E-cadherin) and a 
mesenchymal (N-cadherin) marker. 
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MATERIALS AND METHODS 
 
1. Cell lines and cell culture conditions 
 
Human gastric cancer cell lines, AGS, KATO III, MKN28 and MKN45 were provided from 
American Type Culture Collection (ATCC, Manassas, VA, USA). Two non-commercial cell 
lines, GP202 and IPA220, were established and characterized at IPATIMUP (126). The 
cell lines were maintained in RPMI 1640 Glutamax I supplemented (Gibco, Invitrogen, 
Oregon, USA) with 10% (v/v) fetal bovine serum (Biowest, Nuaillé, France) and 1% (v/v) 
penicillin-streptomycin (10,000 U/mL, Invitrogen, Oregon, USA) medium and cultured in a 
humidified 5% CO2 incubator at 37ºC. 
 
2. Gastric cancer and normal paired samples 
 
Tissue specimens of gastric cancer (n= 30) and matched non-cancer samples, included in 
this study, were obtained from the Tumour Bank at Hospital S. João under an 
institutionally approved protocol and with patient informed consents. All tumour samples 
were classified as adenocarcinomas and subdivided, according to the Lauren 
classification, into intestinal (n= 16) and diffuse (n= 14) types. Samples fulfilled a gross 
examination and representative samples of tumour and non-neoplastic tissue was 
collected and immediately snap frozen in liquid nitrogen (127). A “mirror/twin” sample of 
the frozen tissue was paraffin embedded and heamatoxylin and eosin (H&E) staining was 
performed for morphological characterization. The gross examination and the 
morphological characterization of all tumour samples were performed by the pathologists 
at Hospital S. João. 
 
3. RNA extraction 
3.1. Cell lines 
RNA from cell lines samples was extracted using the mirVana miRNA Isolation Kit  
(AM1560, Ambion, Austin, TX) following the total RNA isolation procedure (including small 
RNAs), which combines 2 RNA extraction methods, namely, organic and solid-phase 
extraction. Initially the samples were disrupted in a denaturing lysis buffer, after which an 
acid-phenol:chloroform extraction was performed. Total RNA purification was performed 
using a filter cartridge containing a glass-fiber filter on which the RNA is immobilized. After 
this procedure the filter was washed and the RNA was eluted with 50μl of UltraPure 
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DNAse/RNAse-Free Distilled Water (Gibco, Invitrogen, Oregon, USA). The RNA quantity 
was assessed by spectrometry using a NanoDrop spectrophotometer (ND-1000 UV-Vis 
spectrophotometer, Thermo Fisher Scientific). 
 
3.2. Tissue specimens 
A volume of approximately 25-30 mm3 was sectioned from each frozen tissue sample and 
cut in small pieces. Subsequently, the tissue was disrupted and homogenized in 700μl a 
Qiazol lysis reagent (QIAGEN, Hilden, Germany) using a Tissueruptor, a handheld rotor-
stator homogenizer (QIAGEN, Hilden, Germany). After 5 minutes of room temperature 
incubation, 140μl of chloroform was added to the sample. After being incubated for 
another 5 minutes the sample was centrifuged for 15 minutes at 12000x g at 4ºC in order 
separate the homogenate into an aqueous and organic phases. The aqueous phase was 
subjected to automatic total RNA extraction in a robotic workstation, QIAcube equipment 
(QIAGEN, Hilden, Germany), where all the purification procedure was completed using a 
spin-column kit (miRNeasy Mini Kit, QIAGEN, Hilden, Germany). The total RNA was 
eluted in 50μl of UltraPure DNAse/RNAse-Free Distilled Water (Gibco, Invitrogen, 
Oregon, USA), quantified by spectrometry (NanoDrop spectrophotometer), and its 
fragment size distribution was analyzed using the Aligent 2100 Bioanalyzer. 
 
4. RT-PCR and quantification of CDH1, Dies1 (C10orf54) and CDH2 mRNA 
expression 
 
A first-strand complementary DNA (cDNA) was obtained from 1μg of total RNA from 
gastric cancer cell lines, commercial total RNA from normal stomach acquired from 
Stratagene (540037-41, Agilent Technologies, Inc., TX, USA), gastric tumours, and 
normal gastric mucosa using random hexamer primers (Invitrogen, Oregon, USA). The 
RNA sample and random primers were incubated for 10 minutes at 70ºC and then placed 
for 2 minutes at 4ºC. The first-strand reaction was catalysed by SuperScript Reverse 
Transcriptase II (Invitrogen, Oregon, USA) for 60 minutes at 37ºC. 
Quantitative real-time PCR (qRT-PCR) was carried out on an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems, California, USA) using the oligonucleotide probe 
approach. Gene expression detection was performed in triplicate for CDH1, C10orf54 
(Dies1), and CDH2 genes, as well as for the endogenous controls GAPDH or 18s RNA, 
using as probes sets: HS.PT.49a.3324071, Hs.PT.58.875102, Hs.PT.58.45367437, 
Hs.PT.51.1940505 (Integrated DNA technologies, Iowa, USA), Hs99999901_s1 (Applied 
Biosystems, California, USA), respectively. PCR reaction of the cell lines was performed 
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using 50ng of cDNA and the TaqMan Universal PCR Master Mix (Applied Biosystems, 
California, USA) in a PCR program with a holding stage of 20 seconds at 50ºC and 10 
minutes at 95ºC, and 40 cycles of 15 seconds at 95ºC and 1 minute at 60ºC. For frozen 
samples a fast-cycling probe-based real-time PCR, Kappa probe fast qPCR kit 
(KapaBiosystems, MA, USA) with the Rox low reference dye was used, with the following 
PCR program: 95ºC for 20 seconds to enzyme activation and 40 cycles of 95ºC for 3 
seconds and 30 seconds at 60ºC. Data were analyzed with the comparative Ct (2-∆∆Ct) 
method. 
 
5. RT-PCR and miR-125a expression quantification 
 
The quantification of mature miR-125a-5p expression was carried out using the TaqMan 
microRNA assay in a two-step qRT-PCR. The reverse transcription was performed with 
10ng of total RNA from gastric cancer cell lines and commercial RNA from normal 
stomach (540037-41, Stratagene, Agilent Technologies, Inc., TX, USA), a stem-loop RT 
specific primer, hsa-miR-125a-5p (RT:002198, Applied Biosystems, California, USA) for 
miR-125a and, NR_002745 (NCBI Accession) (RT:001006, Applied Biosystems, 
California, USA) for RNU48 and the TaqMan MicroRNA reagents (Applied Biosystems, 
California, USA) according to manufacturer instructions. The first-strand complementary 
DNA conversion reaction was performed in a thermal cycler using the following program: 
20 minutes at 16ºC, 30 minutes at 42ºC and 5 minutes at 85ºC. In the PCR step, 
approximately 1.7ng of RT-product was amplified with the TaqMan Universal PCR Master 
Mix and the specific probes hsa-miR-125a-5p (TM:002198, Applied Biosystems, 
California, USA) for target miRNA and NR_002745 (NCBI Accession) (TM:001006, 
Applied Biosystems, California, USA) for endogenous control (RNU48). Real Time PCR 
reactions were performed in triplicate with negative control for each probe using the 
following PCR program: 10 minutes at 95ºC, and 40 cycles of 15 seconds at 95ºC and 1 
minute at 60ºC. Data analysis was carried out with the comparative Ct (2-∆∆Ct) method. 
 
6. DNA extraction 
6.1. Cell lines 
DNA extraction from cell lines was performed using and tracking the Invisob Spin Tissue 
Mini Kit protocol (STRATEC Molecular, Berlin, Germany). Cells were detached with 
trypsin, and the pellet incubated with proteinase K overnight at 52ºC under constant 
shaking (80rpm). After the incubation step, samples were centrifuged at maximum speed 
and the cleared supernatant was carefully transferred to a new 1.5ml tube. DNA 
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purification was accomplished using a silica-based method, and the DNA was eluted in 
50μl of UltraPure DNAse/RNAse-Free Distilled Water (Gibco, Invitrogen, Oregon, USA). 
DNA quantification was performed by quantitative spectrophotometric assay using a 
NanoDrop spectrophotometer. A purified DNA sample was considered with an 
absorbance quotient value of 1.8< OD260/OD280 <2.0. 
 
6.2. Frozen samples 
Similarly to RNA extraction, DNA extraction from frozen tissues was fulfilled in a robotic 
workstation, QIAcube (QIAGEN, Hilden, Germany), using a QIAamp DNA Mini Kit 
(QIAGEN, Hilden, Germany). Approximately 25-35mg of tissue was cut in small pieces, 
transferred to a cold 2ml tube with ATL buffer and homogenized using a Tissueruptor 
(QIAGEN, Hilden, Germany). For protein digestion the samples were incubated overnight 
with proteinase K at 55ºC on constant shaking at 240rpm. After AL buffer addition, the 
samples were transferred to the QIAcube equipment in order to complete the DNA 
extraction protocol. DNA concentration was measure by spectrometry (NanoDrop 
spectrophotometer) and DNA quality was verified by a 1% agarose gel electrophoresis. 
 
7. Bisulfite treatment 
 
In order to predict the existence of CpG islands in Dies1 promoter region a bioinformatical 
analysis was completed using the following criteria: a) genomic length with ≥500 bp; b) a 
percentage of GC content ≥55%; and c) CpG dinucleotides observed/expected ratio 
≥0,65. This analysis was performed using the Ensemble database and the web tool “CpG 
Island Searcher”, which predicted a single CpG island at gene promoter region. The 50 
CpG sites analyzed where located at chr10: 71773310-71773801. 
The method used to analyze the promoter methylation status of the Dies1 gene was 
sodium bisulfite conversion. Treatment with sodium bisulfite leads to a deamination of 
unmethylated cytosines to uracils, while leaving methylated cytosines unchanged since 
the deamination rate of 5-methylcytosine (5mC) to thymine is much slower (128). 
Accepting the different rate of deamination, it is further assumed that cytosines remaining 
after the treatment were derived from 5-methylcytosine. Finally, the treatment products 
are amplified and sequenced for methylation status determination (128, 129). 
Approximately 500ng of cell lines and tumour DNA were used for sodium bisulfite 
treatment with the EpiTeck Bisulfite kit (QIAGEN, Hilden, Germany). The bisulfite 
conversion was performed by mixing the DNA solution, bisulfite mix, DNA protector buffer, 
and DNase/RNase-free water in a thermal cycler using the following protocol:  5 minutes 
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at 95ºC, 25 minutes at 60ºC, 5 minutes at 95ºC, 85 minutes at 60ºC, 5 minutes at 95ºC 
and 125 minutes at 60ºC. The desulfonation and DNA purification was completed in an 
EpiTeck spin column membrane. DNA was further eluted in 20μl of UltraPure 
DNAse/RNAse-Free Distilled Water (Gibco, Invitrogen, Oregon, USA). Bisulfite treatment 
DNA was amplified using primers specifically designed for bisulfite treated DNA 
sequences without CpG sites (Sigma-Aldrich, Missouri, USA) The PCR reaction forward 
and reverse primers are listed in table 1. After amplification, the PCR products were 
purified using Exonuclease I (Ecoli, 20 U/μl, Thermo scientific, Cheshire, UK) and FastAP 
Thermosensitive Alkaline Phosphatase (1 U/µL, Thermo scientific, Cheshire, UK) 
enzymes during 15 minutes at 37ºC and 15 minutes at 85ºC. For methylation status 
determination, the purified PCR products were sequenced using the primers listed in table 
2 and the following program: 2 minutes at 96ºC, 30 cycles of 30 seconds at 96ºC, 30 
seconds at 54ºC and 3 minutes at 60ºC; and 10 minutes at 60ºC. 
In the methylation status analyses all unmethylated cytosines (C) were converted to a 
thymidine (T), and the presence of a C-peak indicated the presence of 5-methylcytocine in 
the genome. A double peak (C andT) indicated that the CpG site was partially methylated. 
 
Table 1 – Sequence of the primers used for PCR amplification of bisulfite treated DNA. 
Amplicon 
ID 
Forward primer Reverse primer 
PCR Product 
Length 
1 5’-GTTAGAGGTAGATTTATTTTTTAGGTTG-3’ 5’-CTATCTTCTCCCAACTTTTTCC-3’ 492 bp 
2 5’-GGAGAGGTAGTTTTTTTATA-3’ 5’-CTATCTTCTCCCAACTTTTTCC-3’ 316 bp 
bp, base pairs. 
Table 2 – Sequence of the primers used for bisulfite treated DNA sequencing. 
Forward primer 
5’-GTTAGAGGTAGATTTATTTTTTAGGTTG-3’ 
5’-GGAGAGGTAGTTTTTTTATA-3’ 
5’-GGTATTAGAAGTTTTTTTG-3’ 
Reverse primer 
5’-CTATCTTCTCCCAACTTTTTCC-3’ 
5’-TATAAAAAAACTACCTCTCC-3’ 
5’-CAAAAAAACTTCTAATACC-3’ 
 
8. Dies1 mutation screening 
 
To accomplish the sequencing of the entire coding sequence of Dies1 gene and the 
predicted target site of miR-125a nine pairs of primers were designed. The designed of 
primers were performed using: (1) Ensemble database to search for the desired sequence 
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and to confirm the specificity of the primer sequence for our target sequence, using for 
that the “Blast” web tool; (2) and the Primer3web software (version 4.0.0) for achieve the 
primers sequence. 
After primer conditions optimization, Dies1 mutations screening was attained using 2 
independent multiplex polymerase chain reactions (PCR), while exons 1, 7 and the latter 
sequence of exon 2 were independently amplified. Multiplex mix 1 contained 3 primers 
sets in order to amplify exons 3, 6 and the predicted target site of miR-125a and the 
multiplex mix 2 contained primers sets for the initiation sequence of exons 2, 4, and 5 
(primers sequences are represented in table 3). Approximately 120ng of DNA was used 
for the amplification reaction, whereas a double of DNA quantity was required for exon1 
amplification, using for PCR reaction a multiplex mix with a 0.2μM of primers and Q-
solution reagent (QIAGEN, Hilden, Germany) (PCR programs are shown in table 4). The 
status of amplification and contamination of PCR products was evaluation by a 2% of 
agarose gel electrophoresis, and the products were purified by enzymatic methods using 
Exonuclease I (Ecoli, 20u/μl, Thermo scientific, Cheshire, UK) and FastAP 
Thermosensitive Alkaline Phosphatase (1 U/µL, Thermo scientific, Cheshire, UK) 
enzymes or by gel band extraction and purification using illustra GFX PCR DNA and a Gel 
band purification kit (GE Healthcare, Buckinghamshire, UK). PCR products purification 
was sequenced using the primers represented in table 3, and PCR program are 
described in bisulfite treatment section. 
 
 Table 3 – Sequence of the primers used in Dies1 mutations screening for polymerase chain reaction. 
    bp, base pairs; seq, sequence 
Reaction Forward primer Reverse primer 
Sequence 
amplified 
PCR 
Product 
Length 
Multiplex 
mix 1 
5'-CTAGCGTGAGAACCTGGGG-3' 5'-TGAGGCCAGAGTTCCAAACA-3' Exon3 250 bp 
5'-GGGATGGGGATGTAGGTGAG-3' 5'-CTCTTCAGGGAGGGCAGG-3' Exon 6 400 bp 
5'-ATGAATGAGGCCTTCCCCAG-3' 5'-CCATGGGGTGAAGAGAAGCA-3' 
Predict target 
site of miR-
125a 
243 bp 
Multiplex 
mix 2 
5'-GGCAGTCTTAGGGAGGTCAG-3' 5'-TGGTGATGGAGAAGTTGCCA-3' 
Initial seq. of 
exon 2 
456 bp 
5'-CTTCCTGGCCTTCCCTCTC-3' 5'-AAGGAATTGTGCCTGCATCG-3' Exon 4 306 bp 
5'-AGGGGCAGGGATGTTGTATG-3' 5'-GCCCCTACTGCACAGAAGTA-3' Exon 5 175 bp 
Reaction 3 5'-CGGTAGAACGGGCTTTAAACTG-3' 5'-GAGTGGGGTGCACGGTCA-3' Exon 1 502 bp 
Reaction 4 5'-CTCACGTTCCAGGACCTTCA-3' 5'-GAGTGCCAGTGTTACCCATG-3' 
Final seq. of 
exon 2 
360 bp 
Reaction 5 5'-GGGATGGGGATGTAGGTGAG-3' 5'-CTCACAGAGCCAGCCCTG-3' Exon 6 and 7 792 bp 
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                       Table 4 – PCR amplification program used in Dies1 mutations screening. 
Step Temperature Time 
Number of 
cycles 
Initial denaturation and 
polymerase activation 
95ºC 15 minutes 1 
Denaturation 94ºC 30 seconds 
2 Annealing 64ºC / 60ºC (reaction3) 90 seconds 
Extension 72ºC 90 seconds 
Denaturation 94ºC 30 seconds 
3 Annealing 62ºC / 58ºC (reaction3) 90 seconds 
Extension 72ºC 90 seconds 
Denaturation 94ºC 30 seconds 
30 Annealing 60ºC / 56ºC (reaction3) 90 seconds 
Extension 72ºC 90 seconds 
Final extension 95ºC 15 minutes 1 
 
 
9. Immunohistochemistry: anti-Dies1 antibody optimization 
 
The antibody optimization was performed in human and mouse tissue species due the 
availability of the tissue material and the necessity to study this protein in the mouse 
tissues. 
 
9.1. Tissue microarray construction 
For construction of a test tissue microarray (TMA) for antibody optimization a diversity of 
tissues were collected from a healthy CBA/N strain mice. The tissues collected were 
immediately immerse in formalin solution, neutral buffered, 10% (approx. 4% 
formaldehyde) and after approx. 55 hours, samples were processed in an automatic 
tissue processor with new reagents to ensure the quality of antigens epitopes, and using 
the followed program: 1 hour in 70% ethanol, 1 hour in 96% ethanol, 3 baths of 1 hours in 
absolute ethanol and 3 baths of 1 hour in heat paraffin wax. The tissues were then 
embedding in an orientation that allowing see all the organ structures, and 2/3μm thick 
section was performed. Tissue sections were then stained with a routine H&E coloration 
and the interested structures were selected and marked on paraffin blocks (figure 4A and 
B). After the selection of the interesting structures a TMA gird was generated using the 
Excel datasheet that contains the tissue coordinates. Some features were taking in 
account in the gird construction: the gird pattern was not completely symmetrical and the 
liver, a characteristic tissue, was included alone in one extreme of the TMA in order to 
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facility its orientation (figure 4C). In this work was used the Arraymold Manual Tissue 
Microarrayer kit (IHC World, LLC, MD, USA) for TMA construction. A receptor block was 
construction using the reusable rubber mold provided by the kit, the receptor block had 35 
cores holes, each one with 3mm of diameter. Using the disposable 3 mm sterile dermal 
biopsy punch, a core of tissue was extracted from selected area of donor block and insert 
in the core hole of receptor block following the X/Y coordinates of the gird pattern 
previously designed (figure 4D and E). Cores holes with no tissue designated were filled 
with a core of paraffin wax. Once all cores holes were completed, the recipient block was 
slightly melted at 37ºC overnight in order to bind the cores into the block, and avoid their 
loss in the section procedure. During this procedure a glass slide was adherent to the 
cores to obtain a plane surface and perform a uniform section.  After a period of room 
temperature resting the slide was slightly removed and sequential 2-3μm sections were 
performed and adherent to a coated glass slide (Superfrost Plus, Gerhard Menzel, 
Braunschweig, Germany). An H&E staining was done to the first section and every after 
10 sections made, to address if the selected tissue areas were still represented in the 
TMA block. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Steps for tissue microarray construction. Selection of interesting structures on A. H&E slide 
and B. paraffin donor block. C. TMA gird generated on Excel database. D. Extraction of a tissue core from the 
selected area on the donor block. E. Core of tissue insert in the recipient block. The steps D and E were 
repeated until complete the predefined TMA plan. F. Final TMA block and test slide.  
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9.2. Immunohistochemistry technique 
Immunohistochemistry (IHC) optimization was performed in TMA sections for mouse 
tissues and for human tissue optimizations this was fulfilled mainly in normal gastric 
tissue, however others tissues were used, such normal spleen, testicle, thyroid, breast 
and placenta tissue. Sections (3μm thick) from paraffin-embedded tissues were 
deparaffinized in xylene and hydrated through a decreasing graded ethanol series. 
Antigen retrieval was performed using 2 different methods: proteolytic and heat induced 
epitope retrieval. In the first method a commercial pepsin solution (DIGEST-AL 3, 
Invitrogen, Oregon, USA) was used for 10 minutes at 37ºC; in the second 2 different heat 
approaches were tested: microwave and IHC-Tek Epitope Retrieval Steamer Set with 2 
different solutions, namely citrate (pH6) or ethylenediaminetetraacetic (EDTA, pH8) buffer 
(Abcam, Cambridge, UK). Slides were allowed to cold down to room temperature, rinsed 
in Tris-buffer saline containing 0.02% Tween 20 (TBS-T) (AMRESCO, OH, USA) at pH 
7.6, and the endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol 
for 15 minutes. Subsequently, the slides were washed in TBS-T, treated with V-block 
solution (TA-125-UB, Thermo scientific, Cheshire, UK) to block nonspecific protein binding 
and incubated with anti-Dies1 antibody (MAB7126 clone 730802 or MAB71261, clone 
730804, R&D Systems) (the specific conditions of each optimization test are described in 
table 5). After being rinsed in TBS-T, the antibody-antigen complex was detected with a 
horseradish peroxidase (HRP) polymer system (Dako REAL EnVision HRP rabbit/mouse, 
Dako, Glostrup, Denmark) for 30 minutes at room temperature, and the antigen 
localization was visualized with 3, 3'-diaminobenzidine (DAB) solution. Finally, the 
sections were counterstained with Gill’s haematoxylin No.2 (Bio-optica, Milano, Italy), 
dehydrated, and mounted using a Richard-Allan Scientific Mounting Medium (Thermo 
Fisher Scientific, MA, USA).  
The table 5 summarizes all the tests performed in order to optimize Dies1 
immunostaining. 
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      Table 5 – Immunostaining conditions tested for anti-Dies1 antibody optimization.  
Optimization 
test 
Antigen Retrieval conditions Antibody 
Antibody 
dilution 
Antibody 
conditions 
1 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer 
R&D Systems, 
clone 730802 
1:100 
Overnight, 4ºC 
2 
IHC-TekTM Epitope Retrieval Steamer Set, 
30 min, Citrate Buffer 
1:100 
3 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, EDTA Buffer 
1:100 
4 Microwave, 20 min, Citrate Buffer 1:100 
5 Proteolytic digestion, 10 min, 37ºC 1:100 
6 - 1:100 
7 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer 
R&D Systems, 
clone 730802 
1:50 
Overnight, 4ºC 8 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer 
1:75 
9 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer 
1:150 
10 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer R&D Systems, 
clone 730802 
1:100 
1hour, Room 
Temperature 
11 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer 
1:100 
30 minutes, 
37ºC 
12 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer 
R&D Systems, 
clone 730804 
1:50 
Overnight, 4ºC 
13 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, EDTA Buffer 
1:50 
14 Proteolytic digestion, 10 min, 37ºC 1:50 
15 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer 
R&D Systems, 
clone 730804 
1:50 
3hours, Room 
Temperature 
16 
IHC-TekTM Epitope Retrieval Steamer Set, 
40 min, Citrate Buffer 
R&D Systems, 
clone 730804 
1:30 
1hour, Room 
Temperature 
 
 
10. E-cadherin and N-cadherin Immunohistochemistry 
 
Automatic immunostaining was performed for E-cadherin and N-cadherin proteins using 
the BenchMark ULTRA, IHC/ISH slide staining system (Ventana Medical Systems, Inc, 
Roche, AZ, USA), after manual optimization of antibodies conditions. 
Formalin-fixed, paraffin-embedded tissue sections (3μm thick) were deparaffinized for 4 
minutes at 72ºC, using EZ-Prep solution (Roche, USA). Tissue pre-treatment was 
conducted with a heat induced epitope retrieval (Roche, USA), at 95ºC for 8 minutes, and 
the endogenous peroxidase was inactivated with UV Inhibitor solution for 4 minutes at 
36ºC. After several washes with the Tris based buffer solution (reaction buffer, pH7.6, 
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Roche, USA), the tissue section was incubated with primary antibody, anti-E-cadherin 
(1:50 dilution; clone 4A2C7; Zymed, South San Francisco, CA) for 28 minutes at 37ºC or 
anti-N-cadherin (1:650 dilution; 610920; BD Transduction Laboratories, New Jersey, USA) 
for 32 minutes at 37ºC. An indirect, biotin-free system, Ultraview Universal DAB Detection 
Kit (Roche, USA) was used to detect the antigen-antibody complex. For this purpose the 
samples were incubated with Ultraview universal HRP multimer (Roche, USA) for 8 
minutes at 36ºC, and with Ultraview universal DAB chromogen for 8 minutes. The contrast 
step was performed automatically using the Hematoxylin reagent (Roche, USA) for 8 
minutes, and the dehydrated, and mounted steps were manually executed. 
 
11. Immunohistochemistry evaluation 
 
IHC results for E-cadherin and N-cadherin were evaluated by a pathologist and scored 
according to the percentage of positive cells, cellular localization of protein, and intensity 
of protein expression (relative to normal expression). E-cadherin expression in normal 
glands and N-cadherin expression in ganglion cells of Meissner’s plexus or Auerbach’s 
plexus served as positive control. An external control, testis sample, was also including in 
N-cadherin staining. 
The staining extension pattern was measured using the following classification: (0), 0-25% 
of positive tumor cells; (1+), 26-50% of positive tumor cells; (2+) 51-75% of positive tumor 
cells and (3+) > 76% of positive tumor cells. For intensity evaluation purposes these 
markers were considered negatives when 0 was scored, and positive staining was scored 
as 1+, 2+, or 3+. The E-cadherin protein cellular localization was classified as normal 
(membrane expression) or aberrant expression (cytoplasmic localization, membrane point 
dot, incomplete membrane expression). 
 
12. Statistical analysis 
 
Differences in expression were estimated by applying an unpaired Student’s t-test for cell 
lines samples analyses. The Wilcoxon’s signed-rank test was applied to compare mRNA 
expression in tumour versus normal tissue and the non-parametric Mann-Whitney U test 
was used for comparing two different groups. The Spearman rho was calculated to find a 
correlation between 2 variables. A p-value< 0,05 was considered statistically significant. 
Graphs and statistical analyses were executed in Prism v6.0 (GraphPad Software, Inc.) or 
in SPSS Statistics v22.0 (IBM SPSS, Inc). 
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RESULTS 
 
The association of Dies1 gene expression to differentiation programs namely, ESC 
differentiation and EMT/MET (group preliminary results), lead us to study this gene in a 
cancer model since cancer cells tend to loose differentiation along with tumour 
progression. Gastric cancer was the model chosen to perform this study. 
Therefore, the first goal of this work was to characterize Dies1 expression in a panel of 
gastric cancer cell lines and find the possible regulatory mechanism that may explain the 
different expression levels of Dies1 in gastric cancer. Also, for a better characterization of 
Dies1 expression in gastric cancer, its mRNA levels were determined in a series of 30 
normal-tumour paired samples. 
The second aim of this work was based on previous results achieved in our group in an in 
vitro EMT/MET model that revealed high levels of Dies1 expression in epithelial states 
and a decrease of its expression in mesenchymal states. E-cadherin loss or down-
regulated expression is a characteristic marker in EMT process that is frequently 
accompanied by an up-regulation of N-cadherin expression. The switch of this cadherin 
proteins are considered a hallmark of EMT and have been described in gastric cancer by 
Lei, et al. (85). Taking these considerations, to accomplish the second goal: “study the 
possible relation of Dies1 expression with epithelial or mesenchymal markers”, the 
previously gastric cancer series characterized for Dies1 expression was used for CDH1 
(encode E-cadherin protein) and CDH2 (encode N-cadherin protein) mRNA levels 
determination. Also the E-cadherin and N-cadherin protein expression was characterized 
by immunohistochemistry in the same cases used for the mRNA expression study. 
 
Preliminary results 
 
Dies1 gene was studied in our group for the first time in an in vitro EMT/MET model. In 
this model, EpH4 mouse mammary epithelial cells (E cells) acquire a mesenchymal (M 
cells) phenotype after stimulated with the TGF-β1 cytokine. This phenotype was reverted 
after the stimulus cession and cell re-acquired the epithelial-like characteristics (“reversion 
E cells”, RE cells). The study of transcription variations during the EMT/MET process 
using the Whole Transcriptome Sequencing, revealed a variation of Dies1 expression. 
This gene was down-regulated when cells lost their epithelial differentiation, M cells, and 
its mRNA levels increased in RE cells that re-acquire an epithelial-like phenotype (figure 
5A). The Dies1 up-regulation, in the mouse EMT/MET model was accompanied by a 
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decrease of the methylation status of Dies1 promoter region, suggesting that this can be a 
possible expression regulatory mechanism in this model (figure 5B). 
Besides the EMT/MET model, a bioinformatics analysis of different gastric cancer series 
revealed a down-regulation of Dies1 in gastric cancer. Also, a preliminary characterization 
of Dies1 expression was performed in a series of 13 primary gastric cancer samples (4 
diffuse, 8 intestinal and 1 mixed type) in comparison with a pool of non-neoplastic gastric 
samples (n= 10) from an available IPATIMUP dataset. In these analyses, 12 of the 13 
gastric cancer samples had a decrease of Dies1 mRNA levels, with a significant variation 
of Dies1 expression (p< 0.05) between the normal stomach pool and the gastric cancer 
samples (figure 5C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Preliminary results of Dies1 expression and promoter methylation status in EMT/MET in 
vitro model and Dies1 mRNA levels in gastric cancer A. Dies1 expression in EMT/MET process. mRNA 
levels of Dies1 in E, M and RE cells. Expression levels were relative to the E cells mRNA level and normalized 
to the corresponding GAPDH mRNA levels. Data are present as means ± SD of duplicates B. Dies1 mouse 
promoter methylation status in E, M and RE cells (n= 2) for CpG sites 19-26 (chr10: 59809756-59809808) 
Black, grey and white circles outlined at black represent methylated, partially-methylated and non-methylated 
CpG sites, respectively. C. Dies1 expression analysed in 13 gastric cancer samples in comparison to a pool of 
normal stomach samples (n= 10). mRNA level was normalized with the corresponding 18S mRNA level. A. 
Unpaired Student’s t-test, B. and Non-parametric Mann-Whitney U test was used, * p < 0.05.  
 
 
*C 
A B 
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1. Dies1 expression characterization and regulatory mechanisms  
 
1.1. Gastric cancer cell lines display down-regulation of Dies1 mRNA levels 
In present work, a panel of 7 gastric cancer cell lines namely, MKN45, IPA220, KATO III, 
AGS, NCI N87, GP202 and MKN28 were cultured in the same conditions and, at 70-100% 
of confluence, DNA and RNA (including small RNAs) extraction were performed. We 
characterized the Dies1 expression using the quantitative real time PCR (qRT-PCR) 
technique for all seven parental gastric cancer cell lines in 3 biological replicas. The 
commercial RNA from normal gastric mucosa was used for normal comparison. 
The majority of cell lines (6/7) revealed a significant decrease of Dies1 expression 
(p<0.05) when compared with the normal counterpart. Indeed the Dies1 mRNA level in 
AGS cell line was almost undetected by qRT-PCR. The NCI N87 cell line demonstrated a 
high heterogeneity in Dies1 expression, among replicates, with a range between 0.4 and 
2.3 fold change (figure 6). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Down-regulation of Dies1 mRNA expression in gastric cancer cell lines. qRT-PCR relative 
quantification of Dies1 expression in gastric cancer cell lines (3 biological replicas). mRNA expression was 
relative to the normal gastric mucosa (RNA commercially available) and normalized using human GAPDH 
endogenous control. Data are present as means ± SD of triplicates. Unpaired Student’s t-test, * p < 0.05.   
 
1.2. Regulatory mechanisms that may lead to Dies1 down-regulation 
Taking into account the previous results that reveal an overall down-regulation of Dies1 in 
gastric cancer cell lines, and in a series of gastric cancer samples, our subsequent 
objective was to find a expression regulatory mechanism that could lead to a decrease of 
Dies1 mRNA levels in this cancer model. 
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1.2.1. Regulatory mechanisms at DNA level: Dies1 gene point-mutations 
Genetic alterations that include point mutations, frameshift deletions and LOH are 
frequently found in gastric cancer and can lead to inactivation of tumour suppression 
genes. The continuous search for new driver gene alterations and the recent advances in 
molecular research has the potential to provide an elucidation or discovery of genes 
inactivated in gastric cancer. In a recent study using the whole-genome sequencing of 
100 tumour-normal pairs for identify a possible new driver mutations in gastric cancer, 2 
non-synonymous base changing alterations were found in Dies1 gene sequence 
(heterozygosity alteration, CT, protein coordinate: L213F; and heterozygosity alteration, 
CA, protein coordinate: N307K) (130). 
Based on these findings, and once the genetics alterations have an important role in 
carcinogenesis, a screening for Dies1 mutations were performed in the gastric cancer cell 
lines used in this study. To achieve this, we sequenced the coding region of Dies1 gene 
(7 exons), the 5’UTR sequence and a partial sequence of the 3’UTR that contains the 
predicted target site for miR-125a-5p. Nine pairs of primers were designed to cover all this 
sequence (figure 7A). The multiplex PCR technique was performed in 2 reactions in order 
to amplify 6 amplicons of the gene (the initial sequence of exon 2, exon 3, 4, 5, and 6 and 
the partial sequence of 3’UTR). However, due the unspecific products formed, 3 
sequences (exon 1, final sequence of exon 2 and exon 7) were independently amplified. 
The gel band extraction and purification was performed before sequencing the exon 7, 
due the presence of an unspecific band after PCR amplification (figure 7B). 
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Figure 7 – Representation of Dies1 gene sequence and electrophorese gel with the amplicons for 
Dies1 mutations screening. A. Schematic representation of Dies1 gene sequence and PCR amplicon 
localization. White and grey squares represent the UTR or translated sequence, respectively. Grey line 
represents the intron region and black lines correspond to specific amplicon localization. B. Representation of 
amplicons in the electrophorese gel for the different reactions realized to Dies1 gene sequencing. Amplicons 
size: E1: 502bp, E2(i): 456bp; E2(f): 360bp; E3: 250bp; E4: 306bp; E5: 175bp; E6: 400bp; E6 + 7(p): 792bp; 
3’UTR(p): 243bp. TSS, transcription start site; E, exon; i, initial, f, final; p, partial.  
 
All PCR products were independently sequenced. Base substitutions were found when 
the gene sequence was compared to its reference sequence, provided by the Ensemble 
database. Two missense substitutions were found, one in exon 1 (CTG  CCG, located 
at chr10:71773420; protein coordinate: L7P ) of the IPA 220 and NCI N87 cell line and the 
other in exon 3 (GAT  GAG, located at chr10:71760875; protein coordinate: D187E) in 
all the cell lines studied. Further analysis revealed that this 2 alterations were already 
reported as single nucleotide polymorphism (SNP), with an allele frequency higher than 
1%, according to the 1000 Genomes Project Phase 1. Others 3 base change alterations, 
with a synonymous consequence and also classified as SNP alterations were detected. In 
all cell lines analysed, no alterations were found in 3’UTR predicted target site for miR-
125a-5p, and this region remain conserved for possible interaction with this microRNA.  
All of the variations found in Dies1 sequencing of the 7 cell lines analysed are resumed in 
table 6. 
A 
B 
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Table 6 – Genetics variations in Dies1 gene sequence of gastric cancer cell lines. 
1 allele frequency according the 1000 Genomes Project Phase1; 
Abbreviations: SNP, single nucleotide polymorphism; Asp, aspartic acid; Glu, glutamic acid; Leu, leucine; Pro, proline; Val, 
valine. 
 
 
 
1.2.2. Regulatory mechanisms at DNA level: Dies1 promoter methylation 
Besides genetic alterations, epigenetics alterations have also an important role in gastric 
carcinogenesis. DNA methylation is one of the widely characterized epigenetics 
modifications and characteristic changes have been reported in many diseases such 
cancer (131). This mechanism comprises an addition of a methyl group in the fifth carbon 
position of a cytosine residue in a CpG dinucleotide. The clusters of CpG dinucleotide 
(CpG islands) are frequently located at transcription start sites (promoter), and its 
methylation is generally association with closed chromatin state and inhibition of promoter 
activity (132, 133). 
In gastric cancer, diverse genes have been shown to have an association between 
expression down-regulation and promoter methylation. Taking in account the relevance of 
this regulatory mechanism in cancer and the preliminary results that revealed a possible 
relation between Dies1 expression and the status of promoter methylation in the 
Samples Exon Alleles 
Allele 
change 
Variation class 
and reference 
Allele 
frequencies1 
Protein residue 
change 
Consequence 
type 
MKN45 3 (G/G) GAT ⇒ GAG SNP rs3747869 T: 12%; G: 88% D [Asp] ⇒ E [Glu] Missense 
IPA220 
1 (C/C) CTG ⇒ CCG SNP rs3747862 T: 70%; C: 30% L [Leu] ⇒ P [Pro] Missense 
2 (A/A) GAG ⇒ GAA SNP rs3747867 G: 79%; A: 21% E [Glu] ⇒ E [Glu] Synonymous 
3 (G/G) GAT ⇒ GAG SNP rs3747869 T: 12%; G: 88% D [Asp] ⇒ E [Glu] Missense 
KATO III 
2 (G/A) GAG ⇒ GAA SNP rs3747867 G: 79%; A: 21% E [Glu] ⇒ E [Glu] Synonymous 
3 (G/G) GAT ⇒ GAG SNP rs3747869 T: 12%; G: 88% D [Asp] ⇒ E [Glu] Missense 
AGS 
2 (C/T) GAC ⇒ GAT SNP rs3747866 C: 82%; T: 18% D [Asp] ⇒ D [Asp] Synonymous 
3 (G/G) GAT ⇒ GAG SNP rs3747869 T: 12%; G: 88% D [Asp] ⇒ E [Glu] Missense 
NCI N87 
1 (T/C) CTG ⇒ CCG SNP rs3747862 T: 70%; C: 30% L [Leu] ⇒ P [Pro] Missense 
2 (T/T) GAC ⇒ GAT SNP rs3747866 C: 82%; T: 18% D [Asp] ⇒ D [Asp] Synonymous 
3 (G/G) GAT ⇒ GAG SNP rs3747869 T: 12%; G: 88% D [Asp] ⇒ E [Glu] Missense 
7 (C/T) GTC ⇒ GTT SNP 
rs114278565 
C: 97%; T: 3% V [Val] ⇒ V [Val] Synonymous 
GP202 3 (G/T) GAT ⇒ GAG SNP rs3747869 T: 12%; G: 88% D [Asp] ⇒ E [Glu] Missense 
MKN28 
2 (C/T) GAC ⇒ GAT SNP rs3747866 C: 82%; T: 18% D [Asp] ⇒ D [Asp] Synonymous 
2 (A/A) GAG ⇒ GAA SNP rs3747867 G: 79%; A: 21% E [Glu] ⇒ E [Glu] Synonymous 
3 (G/G) GAT ⇒ GAG SNP rs3747869 T: 12%; G: 88% D [Asp] ⇒ E [Glu] Missense 
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EMT/MET model, the promoter methylation was studied as a possible mechanism leading 
to down-regulation of Dies1 gene in gastric cancer cell lines. 
The search for the possible presence of a CpG island in promoter region of human Dies1 
gene was further accomplish in our group, by a bioinformatics analyses. This search 
detected a possible CpG island in Dies1 transcription start site and we analysed 50 CpG 
sites located at chr10: 71773310-71773801, using the sodium bisulfite genome 
sequencing method. The sodium bisulfite treatment leads to a deamination of non-
methylated cytosine to uracil that is replaced by thymine after PCR amplification. 
Methylated cytosine remains intact (without base change). The DNA methylation status 
was interpreted by comparison the sequencing results with the original DNA sequence, in 
this way the presence of a cytosine indicated the existence of a methylated nucleotide, 
and the presence of a converted thymine indicated a non-methylated nucleotide. The 
presence of both C- and T- peak was considered as a partially methylated CpG site 
(figure 8A). 
The analyses interpretation of the promoter methylation status results revealed that the 
AGS cell line presented a high number of CpG sites methylated, and the GP202 cell line 
had the CpG island predominantly partially methylated (figure 8B). These promoter 
methylation results were associated with down-regulation of Dies1 mRNA levels, 
suggesting that this may be a regulatory mechanism of Dies1 expression in these 2 cell 
lines. Also the NCI N87 cell line, that did not have a significant variation of Dies1 
expression, presented an unmethylated CpG island (figure 8C). Despite these results, the 
remaining cell lines analysed did not display a methylation profile of CpG island in Dies1 
promoter region but presenting a down-regulation of Dies1 mRNA levels, suggesting that 
others mechanism could be leading to a decrease of gene expression. 
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Figure 8 – Dies1 promoter methylation status in gastric cancer cell lines. A. Interpretation of the 
methylation sequencing electropherogram results. The figure shows a portion of Dies1 promoter region of 
AGS cell line (CpG sites 16, 17, 22 and 23). CpG sites are underlined at black and cytosines in non-CpG sites 
converted to thymine are indicated with a circle. CpG site with the cytosine converted to thymine represented 
a non-methylated site, the presence of 2 peaks (T- and C- peak) indicates partial methylation, and the 
existence of the cytosine in electropherogram result indicates the presence of 5mC in the genome. B. Dies1 
mRNA expression variation in gastric cancer cell lines and C. the corresponding promoter methylation status. 
Each horizontal row of circles represents one cell line analyses of bisulfite-treated DNA in 50 CpG sites of 
Dies1 promoter region (chr10: 71773310-71773801). Black, grey and white circles outlined at black represent 
methylated, partially-methylated and non-methylated CpG sites, respectively. White circles outlined at grey 
correspond to CpG sites not analyzed. Unpaired Student’s t-test, * p < 0.05.   
 
1.2.3. Regulatory mechanisms at RNA level: regulation by miR-125a-5p 
Taking in consideration the regulatory mechanisms previously studied for this gene, the 
gene regulation by microRNAs, namely by miR-125a-5p was also studied in gastric 
cancer cell lines. 
Parisi et al. (18) reported that mouse Dies1 3’UTR sequence has a predicted target site 
for miR-125a. In that work, it was also proved that the overexpression of miR-125a lead to 
a down-regulation of Dies1 protein levels. To estimate if the human homologue miR-125a-
5p, can be a possible target for human Dies1 transcript, we used 2 approaches: first of all, 
using the Ensemble database, we uncovered that the human Dies1 3’UTR sequence 
contains the predicted target-site for miR-125a-5p, and the sequence of this miRNA, was 
0.0 0.5 1.0 3.0
MKN28
GP202
NCI N87
AGS
KATO III
IPA220
MKN45
Normal
stomach
Dies1 mRNA expression
*
*
*
*
*
*
A 
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conserved between mouse and human species (figure 9A). In a second analysis, using 
the database on predicted and validated miRNA targets, miRWalk, we confirmed that the 
human Dies1 mRNA 3’UTR region has a predicted seed region for miR-125a-5p. 
Taking these analyses in consideration, and in order to find if there was a relationship 
between Dies1 and miR-125a-5p expression, the level of this microRNA was measured by 
qRT-PCR. 
This analysis revealed that 3 of the 7 cell lines studied, namely AGS, NCI N87 and 
MKN28 had an increase of miR-125a-5p expression (p> 0.05) compared with normal 
stomach mucosa. The others 4 cell lines, 3 (MKN45, IPA220 and GP202) had a decrease 
of expression of this miRNA compared with normal stomach mucosa (p< 0.05), and KATO 
III had only a slight reduction of miR-125a-5p expression compared with normal stomach 
mucosa (p= 0.017). AGS and MKN28 cell lines had an increase of the miR-125a-5p 
expression (p= 0.219; p= 0.316, respectively) concomitant with the down-regulation of 
Dies1 mRNA levels, and the cell line KATO III had a higher expression of miR-125a-5p 
when compared to Dies1 expression (figure 9B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – miR-125a-5p expression correlation with Dies1 gene expression. A. Bioinformatics predicted 
target site of miR-125a-5p in 3’UTR of Dies1 in human and mouse species. The seed region (represented at 
bold) and the miR-125a-5p sequence are conserved regions between mouse and human species. B. qRT-
PCR relative quantification of Dies1 (results represented in figure 6) and miR-125a-5p expression levels in 
gastric cancer cell lines. The miR-125a-5p expression levels were normalized using the endogenous control 
RNU48 and also normalized to the expression levels observed in commercial RNA from normal gastric 
mucosa. Data are present as means ± SD of 2 biological replicates. Statistical analyses correspond to the 
comparison of gene expression with correspondent expression in normal stomach. Unpaired Student’s t-test,  
* p < 0.05.   
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1.3. Human gastric cancer and Dies1 expression 
For a better characterization of Dies1 expression in gastric cancer a series (n= 30) from 
Portuguese patients were obtained from Hospital S. João’s tissue tumour bank. The DNA 
and RNA extraction was completed from frozen gastric cancer samples and their normal 
sample pair. Dies1 mRNA levels were measure by qRT-PCR. Due to technical problems, 
only 25 cases were eligible for Dies1 expression analyses (intestinal type n= 13, diffuse 
type n= 12). 
The analysis of the overall Dies1 expression revealed a statistically significant difference 
(p= 0.016) between normal tissues and tumour samples, where the tumour tissue had an 
increase of Dies1 expression (figure 10A and B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Expression quantification of Dies1 in gastric cancer samples. A. Box plots represent the 
mRNA expression levels of Dies1 relative to 18S in 25 normal gastric mucosa and gastric cancer samples. 
Statistically Wilcoxon Signed Ranks test was performed to obtain p value. * p < 0.05. B. Zoom of graphic A.  
 
Subsequently we evaluated the Dies1 expression in the 2 different histological subtypes 
following the Lauren´s classification: intestinal and diffuse type. An increased expression 
of Dies1 in intestinal tumours was observed when compared with normal pairs (p= 0.023), 
and the diffuse subtype showed the same trend without statistical significance (figure 11A 
and B). 
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Figure 11 – Dies1 expression in gastric cancer histological subtypes. A. Box plot represent Dies1 mRNA 
expression levels relative to 18S, subdivided by histological subtypes. B. Zoom of graphic A. Statistically 
Wilcoxon Signed Ranks test was performed for paired samples (normal/tumour). * p < 0.05; n.s., not-
significant. 
 
The individual analyses of Dies1 mRNA levels compared with the normal counterpart 
reveal that, contrary to the preliminary results, 14 of 25 (56%) gastric cancer samples had 
an increase of Dies1 expression when compared with the normal tissue, higher than 1.5 
fold change. About 32% (8/25) of these cases belong to the intestinal histological subtype 
and 24% (6/25) belong to the diffuse type. Six of 25 (24%) tumour samples had a 
decreased expression similar to the previous analysis in cell lines and in the first series of 
gastric cancer samples, 4 of these cases were classified as diffuse type. The remaining 5 
of 25 (20%) tumour cases exhibited only a slight variation of Dies1 mRNA levels (figure 
12). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 - Relative Dies1 expression in tumours vs. corresponding normal (n= 25). Dies1 mRNA level 
was normalized with the corresponding 18S mRNA level. Data are present as means ± SD of technical 
duplicates or triplicates. The dashed lines correspond to the limits in which the expression is considered 
increased (1.5 fold higher) or decreased (0.66 fold lower) relative to corresponding normal. 
 
* n.s. 
 
* n.s. 
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Focusing on tumours with a down-regulation of Dies1 expression in comparison with the 
corresponding normal and, similar to the results obtained for cell lines, we analysed one of 
the mostly likely expression regulatory mechanism: promoter methylation. In order to do 
that, the DNA of the 6 tumour samples with down-regulation of Dies1 expression was 
treated with sodium bisulfite. Also, as a negative control a normal DNA sample was 
bisulfite converted. Bisulfite treatment of AGS cell line DNA was used as technical positive 
control. None of the 6 tumours with down-regulation of Dies1 expression, and similarly to 
the normal sample, presented CpG island methylation (figure 13), suggesting that other 
regulatory mechanisms may be responsible for the alteration of Dies1 gene expression. 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Promoter methylation status of gastric cancer tumours with a decrease of Dies1 
expression relative to normal counterpart. AGS cell line functioned as technical positive control and normal 
stomach was used as a methylation negative control. Each horizontal row of circles represents one tumour 
sample analyzed for 50 CpG sites of Dies1 promoter region (chr10: 71773310-71773801). Black, grey and 
white circles outlined at black represent methylated, partially-methylated and non-methylated CpG sites, 
respectively. White circles outlined at grey correspond to CpG sites not analyzed. 
As methylation does not explain Dies1 loss in these gastric cancers, it remains to be 
further analysed the expression of miR-125-5p in the gastric cancer series.  
 
1.4. Dies1 protein characterization 
In order to characterize the Dies1 protein expression on gastric normal tissue, with the 
main goal of understanding the impact of Dies1 down-regulation at the RNA level, IHC 
optimization was performed in paraffin-embedding tissues, with antibodies against Dies1. 
Dies1 IHC optimization was performed in a TMA with mouse tissues and in normal human 
gastric mucosa. The TMA was used for better characterization of this protein in different 
normal tissues. The TMA construction was also performed for other antibody 
optimizations. 
To achieve Dies1 antibody optimization, we performed different experiments using for that 
different antigen retrieval approach: different methods (heat and proteolytic digestion 
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  55 
methods) and different buffer solutions (EDTA and citrate buffer). Also, different antibody 
concentrations and incubation times were tested (table 5, material and methods 
chapter). Besides the apparent specific staining accomplished in mouse tissues, in 
human samples this staining was heterogeneous with different staining patterns even after 
optimization of the best antibody condition (R&D Systems, clone 730802; antigen 
retrieval: IHC-Tek Epitope Retrieval Steamer Set, 40 min, Citrate Buffer; antibody 
condition: dilution 1:100 at overnight, 4ºC; figure 14 and 15). Predominantly in human 
samples, but also in mouse samples, IHC results, in same conditions, and in sequential 
tissue sections, were variable and not trustable (figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 – Dies1 immunohistochemistry staining in normal human gastric mucosa. The staining was 
performed in 2 independent experiments using the same block sections and following the same protocol 
conditions (optimization test 1, table 5). A. and B. In experiment 1 the antibody seems to stain the gastric 
glands and some stromal cells. C. and D. In experiment 2 there are no staining in glandular, only some 
staining was seen in stromal cells. A. and C. original magnification ×40; B. and D. original magnification ×200. 
 
Besides this technical problem, the Dies1 protein, in mouse, seems to be present in 
different tissues, mainly in muscle, gastric mucosa, spleen, colon and pancreas with a 
cytoplasmic/membrane staining (figure 15). However this results should be further 
confirmed. 
The acquisition of a new antibody did not solve the immunostaining problems once no 
staining was obtained neither by immunohistochemistry, immunocytochemistry or western 
blot techniques. The acquisition or production of a new antibody is likely necessary for 
further characterization of Dies1 protein in different tissues, in normal gastric mucosa and 
in gastric cancer. 
Experiment 1 Experiment 2 
A 
B 
C 
D 
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2. Dies1 mRNA expression correlation with epithelial and mesenchymal markers 
The analyses of CDH1 and CDH2 expression had the main objective of evaluating the 
expression correlation between Dies1 and an epithelial and a mesenchymal marker 
(CDH1 and CDH2 respectively), in our gastric cancer series. The series was not 
completely characterized for the 3 gene studied (CDH1, Dies1 and CDH2) due some 
technical problems, mostly related with the RNA quality. 
 
2.1. CDH1 and CDH2 mRNA expression in gastric cancer 
CDH1 mRNA levels were obtained for 27 gastric cancer samples (14 intestinal type, 13 
diffuse type), 74.1% (20/27) of these cases presented CDH1 up-regulation (≥ 1.5 fold 
change when compared with the normal pair). This increased expression correspond to 
85.7% (12/14) of intestinal type tumours and 61.5% (8/13) of diffuse type tumour cases. 
Only 4 of 27 cases (14.8%) presented a decreased expression of this gene, when 
compared with the normal pair (≤ 0.66 fold change), and 3 of these were histologically 
classified as diffuse type. The remaining 3 tumour cases (11.1%, 3/27) exhibited only a 
slight variation of CDH1 mRNA levels. As predicted by results described above, the 
overall difference of CDH1 mRNA levels between normal and tumour samples was 
statistically significant with an increased expression observed in tumour samples (p< 0.00) 
(figure 16A and B). The evaluation of CDH1 expression by histological subtypes also 
revealed an up-regulation of this gene in the intestinal tumour subtype when compared to 
normal pair (p= 0.001), in diffuse type this difference was subtle (p= 0.101). Data 
dispersion reveals a difference in CDH1 expression between intestinal and diffuse 
histological tumour samples, where intestinal tumours present a higher expression than 
the diffuse tumour type. Besides this visual difference, these results were not statistically 
significant (p= 0.073) (figure 16C and D). 
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Figure 16 – Characterization of CDH1 mRNA expression in the gastric cancer series. mRNA expression 
of CDH1 relative to 18S in 27 normal gastric mucosa and gastric cancer samples A. Boxplots represent the 
expression in normal and gastric cancer samples. Gastric cancer shown an up-regulation of CDH1 expression 
(p< 0.00) when compared with normal pair B. Zoom of graphic A. C. CDH1 expression by histological type, 
intestinal type n= 14, diffuse type n= 13. CDH1 had an increase expression in intestinal tumour samples 
compared to their normal pair (p= 0.001), and no significant difference exists in diffuse type. D. Zoom of 
graphic C. Statistically Wilcoxon Signed Ranks test was performed for paired samples (normal/tumour). * p < 
0.05, n.s., not-significant. 
 
The analysis of CDH2 expression was performed in 22-paired samples (9 intestinal type, 
13 diffuse type). We verified that 31.8% (7/22) of tumour samples displayed an up-
regulation of expression when compared to the normal counterpart, where 9.1% (2/22) of 
these was classified as intestinal type, and 22.7% (5/22) as diffuse type. About 45.5% 
(10/22) of tumour samples had a down-regulation of CDH2 expression and 22.7% (5/22) 
had no expression variation. The overall mRNA expression levels did not vary between 
the tumour and normal counterpart samples, p> 0.05 (figure 17A and B). Also there was 
no difference in CDH2 expression between the tumour and normal paired samples related 
with the histological type, neither between the diffuse and intestinal tumour expression,  
p> 0.05 (figure 17C and D). 
 
 
 
 
 
 
 
 
 
C D 
                             * 
 
    * n.s. 
 
n.s. 
 
n.s. 
 
 
n.s. 
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Figure 17 – mRNA expression of CDH2 in gastric cancer tumour samples. mRNA expression levels of 
CDH1 relative to 18S in 22 normal gastric mucosa and gastric cancer samples. A. Boxplots represent the 
expression in normal and gastric cancer samples. CDH2 overall expression showed a similar expression 
between normal and tumour samples. B. Zoom of graphic A. C. CDH2 expression by histological type, 
intestinal type n= 9, diffuse type n= 13. D. Zoom of graphic C. Statistically Wilcoxon Signed Ranks test was 
performed for paired samples (normal/tumour). n.s., not-significant. 
 
After characterization of 3 evaluated markers both Dies1 and CDH1 expression revealed 
a significant increased expression between normal and tumour samples. Also in both, this 
difference was presented in intestinal type but not in diffuse histotype.  
 
2.2. Dies1 expression seems to correlate with CDH1 expression in gastric cancer 
samples 
With the main objective to study the correlation of Dies1 expression with an epithelial 
(CDH1) and a mesenchymal (CDH2) marker, the gastric tumour samples with the eligible 
results for the 3 genes was used for performing this analyses. This corresponded to a total 
of 19-paired samples (intestinal type n= 8, diffuse type n= 11). The tumour mRNA 
expression results were normalized for expression of the matching normal sample. 
The analyses of data dispersion revealed that CDH1 expression was higher in tumour 
than in normal in more than 75% of the cases, and that Dies1 expression was higher in 
tumour than in normal in more than 50% of the cases. In contrast tumour samples 
presented a lower expression of CDH2 in more than 50% of tumour compared to 
matching normal sample (Figure 18A).  
Analysing the tumour samples by histologic subtypes, the expression of CDH1 seems to 
be higher in intestinal type than in diffuse type. The same trend was verified in Dies1 
expression, and by evaluating the data dispersion, this gene seemed to have a higher 
expression in intestinal type in comparison to the diffuse type. No difference seems to 
exist between the 2 histological types concerning the CDH2 mRNA levels (Figure 18B). 
C D 
n.s. n.s n.s. n.s. 
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Figure 18 – CDH1, Dies1 and CDH2 expression levels variations in 19 tumours samples normalized for 
normal pair. A. Box plots represent mRNA expression level relative to normal pair. B. Relative mRNA 
expression divided by histological type. Intestinal tumours samples showed a higher expression of CDH1 and 
Dies1 compared to diffuse type. CDH2 expression had the same expression in both histological subtypes. 
 
 
The individual analyses demonstrated that in 17 of the 19 cases CDH1 and Dies1 
expression levels follow the same tendency (figure 19, blue outlined squares). However 
in 3 of these cases, namely tumour case 15, 22 and 27, one of the gene variations is near 
to the normal expression when the other had an overexpression higher that 1.5 fold 
change or a decrease expression lower than 0.66 fold change in comparison with the 
normal paired sample. In only 2 cases CDH1 and Dies1 expression did not follow the 
same trend (tumour cases 13 and 19). In 11 cases, the 3 genes studied had the same 
expression tendency, in 8 of them CDH1, Dies1 and CDH2 had an overexpression higher 
that 1.5 (n= 4) or a decreased expression lower than 0.66 (n= 4) fold change (figure 19). 
 
 
 
 
 
 
 
 
 
A B 
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Figure 19 – Individual case analyses of CDH1, Dies1 and CDH2 relative mRNA levels variation. mRNA 
expression normalized for the normal pair. (1) The first 4 tumour cases had an expression down-regulation of 
the 3 analysed genes. Tumour case 13 and 19 were the only tumours with an opposite expression tendency 
of CDH1 and Dies1 genes. (2) Six tumour cases had an up-regulation of CDH1 and Dies1 expression and an 
opposite tendency of CDH2 expression level. (3) Seven cases had an overexpression or a slight increase of 
the CDH1, Dies1 and CDH2 expression levels in tumour samples. mRNA expression levels was relative to the 
corresponding 18S mRNA level. The dashed lines correspond to the limits in which the expression is 
considered increased (1.5 fold higher) or decreased (0.66 fold lower) relative to corresponding normal. 
 
The above results demonstrated that most cases showed a similar mRNA expression 
tendency between Dies1 and CDH1 genes. Following these results a correlation analyses 
was performed for the 3 genes. This analysis revealed that there was no correlation 
between CDH1 and CDH2 mRNA levels (p= 0.180). The same results were achieved for 
CDH2 and Dies1 correlation analyses in the overall cases (p= 0.314). The correlation 
analyses revealed a statistically significant relationship between the expression of Dies1 
and CDH1 markers (p< 0.01), and the dispersion data analyses lead us to hypothesise 
that Dies1 and CDH1 mRNA relative expression followed the same trend. 
 
 
2.3. Immunoreactivity of E-cadherin and N-cadherin 
The protein expression does not always follow the mRNA expression and the ratios 
between protein and mRNA are mainly determined by translation and protein degradation. 
(134) Additionally, even when protein is present, a high number of post translation 
modifications can affect the protein function. Often E-cadherin protein presents an 
aberrant expression in cancer due to de-localization from the cell membrane to the 
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cytoplasm, but the mRNA level remain the same, while the protein function becomes 
impaired. Taking this in account the immunohistochemistry protein characterization of our 
gastric cancer series was performed for E-cadherin and N-cadherin proteins. Due the 
heterogeneous staining, previously achieved in human tissues, it was not possible to 
characterize Dies1 at protein level. 
The IHC technique was performed in the 19 tumours cases previously analysed at mRNA 
level. The immunostaining was accomplished in an automatic slide staining for ensure the 
same conditions in all tumour samples, and normal epithelial cells and ganglion cells 
functioned as positive control for E-cadherin and N-cadherin, respectively. 
N-cadherin protein was not detected neither in normal epithelial mucosa neither in any of 
the tumour cases analysed, including the cases with an overexpression of the mRNA level 
when compared to the normal tissue (figure 20A, table 7). The specific positivity staining 
in internal positive control cells excluded the existence of technical problems (figure 20B). 
E-cadherin protein staining was evaluated by comparing the expression of tumour cells 
with normal epithelial cells. Only 3 tumour cases, which belong to the intestinal subtype, 
presented a normal E-cadherin membranous expression (figure 20C). The remaining 
cases presented aberrant expression pattern such as: cytoplasmic staining, incomplete 
cell membranous staining, or an aberrant doted pattern (figure 20D, E, F). From the 5 
intestinal cases with decreased intensity of the protein expression, only 1 had a 
concomitant decrease of mRNA expression; the other 4 cases, 2 had an increased 
expression and 1 had the same expression in normal and tumour sample. Also, the E-
cadherin positivity, in tumour 10, was found in less than 25% of tumour cells, however 
mRNA levels were higher in tumour than the normal pair. In diffuse histological type, all 
tumour cases exhibit an abnormal pattern of E-cadherin staining, 4 tumour cases was no 
E-cadherin staining and 2 had expression in less than 25% of tumour cells. In these 6 
cases the mRNA level only had a correlation with the protein level in 1 case (T21), the 
other 5 presented an up-regulation or no variation of CDH1 expression in comparison with 
the normal tissue. In tumour 30, mRNA expression was decreased, but 90% of tumour 
cells had a normal positive staining and only 10% had an aberrant staining pattern.  
 
The mRNA expression results of the 3 genes and the IHC results are resumed in table 7.
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Figure 20 – N-cadherin and E-cadherin immunostaining. A. No staining was achieved for N-cadherin 
protein. Tumour 23, original magnification ×100 B. N-cadherin positive intern control, ganglion cells, Tumour 
23, original magnification ×40. C. D. E and F. Different E-cadherin immunostaining pattern on gastric cancer 
cells: C. Normal pattern; Tumour 07, original magnification ×200; D. Cytoplasmic staining; Tumour 15, original 
magnification ×200; E. Dot point pattern mainly on cell-cell contact; Tumour 19, original magnification ×600; F. 
Incomplete membrane staining; Tumour 10, original magnification ×400. 
Table 7 – Summary of mRNA and protein expression of the analysed genes: Dies1, CDH1, CDH2. 
The mRNA values were relative to the normalized expression of genes in tumour samples: -1, <0.66 fold change; 0, values 
between 1.5 and 0.66 fold change; 1, >1.5 fold change. Protein evaluation: Intensity: 0, no staining, 1+, weak staining, 2+, 
moderate staining 3+, strong staining. Positive cells: 0, 0-25%; 1+, 26-50%; 2+, 51-75%; 3+, > 76% of positive tumour cell.
 
Dies1 
expression  CDH1 or E-cadherin expression  
CDH2 or N-cadherin 
expression 
Tumour 
ID mRNA 
 mRNA 
Protein  mRNA 
Protein 
 Intensity Protein pattern 
Positive 
cells  
Positive 
cells 
Intestinal type (n= 8) 
T01 1  1 1+ Aberrant (incomplete) (3) > 76%  -1 0 
T04 -1  -1 1+ Aberrant  (incomplete) (2) 50-75%  -1 0 
T07 1  1 3+ Normal (3) > 76%  -1 0 
T10 1  1 1+ 
Aberrant  (incomplete and 
heterogeneous expression) (0) < 25%  1 0 
T12 1  1 3+ Aberrant  (incomplete) (3) > 76%  1 0 
T13 -1  0 1+ Normal (3) > 76%  0 0 
T14 1  1 2+ Normal (3) > 76%  0 0 
T15 0  1 1+ 
Aberrant  (incomplete and 
cytoplasmic) (3) > 76%  0 0 
Diffuse type (n= 11) 
T18 1  1 2+ Aberrant  (dot point) (3) > 76%  1 0 
T19 -1  1 2+ 
Aberrant  (incomplete and 
dot point) (2) 50-75%  -1 0 
T21 -1  -1 0 - (0) < 5%  -1 0 
T22 0  1 1+ 
Aberrant  (incomplete, dot 
point and cytoplasmic) (0) < 25%  1 0 
T23 0  0 1+ 
Aberrant  (incomplete and 
dot point) (0) < 25%  1 0 
T24 -1  -1 2+ 
Aberrant  (incomplete and 
dot point) (2) 50-75%  -1 0 
T26 1  1 0 - (0) < 25%  1 0 
T27 1  0 1+ 
Normal (Superficial cells); 
Aberrant (Profound cells: 
incomplete, dot point and 
cytoplasmic) 
(2) 50-75%  1 0 
T28 1  1 0 - (0) 0%  0 0 
T29 1  1 0 - (0) 0%  0 0 
T30 -1  -1 2+ 
Normal (90%), Aberrant  
(dot pattern, 10%) (3) > 76%  -1 0 
A B 
C D E F 
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DISCUSSION 
 
In this thesis, we aimed to (1) characterize the Dies1 expression in gastric cancer cell 
lines and tumour samples, and explore the possible expression regulatory mechanisms of 
this gene, and; (2) analyse the expression relationship of Dies1 with an epithelial (E-
cadherin) and a mesenchymal (N-cadherin) marker. Overall, and in relation to aim 1, we 
observed that Dies1 expression is modulated differentially in gastric cancer cell lines and 
primary tumours, potentially due to 2 possible mechanisms, promoter methylation and 
regulation by miR-125a-5p. Concerning the results related with aim 2, we observed that 
Dies1 expression seems to follow the expression of the epithelial marker, CDH1. 
 
The contribution of Dies1 in mESC differentiation into neurons, astrocytes, 
cardiomyocytes and pre-adipocytes into adipocytes pointed for the important role of this 
gene in embryonic differentiation program (1, 5). Also in a distinct differentiation context, 
such as EMT/MET, Dies1 seems to follow the epithelial cell differentiation. In EMT, cells 
usually lose their epithelial differentiation and characteristics and acquire a mesenchymal 
phenotype, this process can be reverted and cell re-acquires the epithelial characteristics 
(MET) (33, 36-38). In the EMT/MET in vitro model established in our group, Dies1 mRNA 
levels accompanied the loss of epithelial differentiation with a decreased expression in 
cells that undergo EMT, and a re-acquisition of its mRNA levels when cells return back to 
an epithelial like phenotype. In this preliminary result Dies1 seemed to have a similar 
behavior to a characteristic epithelial marker.  
The involvement of Dies1 in 2 differentiation programs led us to study its expression in a 
gastric epithelial cancer model, where cells frequently presents some degree of de-
differentiation along with cancer progression.   
The first approach to study Dies1 gene in gastric cancer was analyzing its expression in a 
set of gastric cancer cell lines. This gene revealed a decreased expression in the majority 
(6/7) of gastric cancer cell lines studied. These results are consistent with the preliminary 
results that described a decrease expression of Dies1 in 13 gastric cancer samples 
compared with a pool of normal gastric samples. Only 1 cell line evaluated did not have a 
decrease in the expression of this gene, and curiously this was the only cell line 
characterized as a well-differentiated gastric cancer cell line (126, 135). The down-
regulation of Dies1 led us to hypothesis about the possible regulation mechanism that 
leads to a decreased expression in gastric cancer cell lines.  
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Gastric carcinogenesis is a complex multistep process, and numerous studies indicate 
that the development and progression of gastric cancer arises via misregulation of 
numerous genes. The accumulation of genetic and epigenetic alterations in different 
proto-oncogenes and tumor-suppression genes culminates in cellular behavior 
modification, and increased evidence has emerged that genetic and epigenetic 
mechanisms acts in combination and take advance of each other during tumorigenesis 
(77, 89, 136). Genetic alteration, such as mutations is a frequent mechanism that leads to 
a down-regulation of some genes in gastric cancer, such TP53 and CDH1. (50, 108, 137) 
Loss of heterozygosity is a common mechanism associated with biallelic inactivation, 
besides the genetics modifications, epigenetics alterations such as promoter 
hypermethylation is an important event associated with loss of gene expression (50, 137). 
The promoter methylation status has been described to be responsible for down-
regulation of many tumour suppression and tumour related genes in gastric cancer, such 
MSH2 (MutS protein homolog 2), MLH1 (mutL homolog 1), p16 and RUNX3. (137). These 
genetics and epigenetic regulatory mechanisms cannot explain all down-regulated gene 
alterations in gastric cancer. Taking the example of E-cadherin, Corso, et al. described 
that a high percentage of cases with alterations of E-cadherin protein expression did not 
have structural mechanisms (mutations and LOH) neither promoter hypermethylation, 
suggesting the presence of different inactivating mechanisms (108). These different 
mechanisms can include the regulation by microRNA, transcription factors repressors, 
and also posttranslational mechanisms, such aberrant N-glycosylation and proteolytic 
cleavage that can result in a deregulation of E-cadherin function (50, 106, 107).   
 
In a first approach to find the expression regulation mechanism of Dies1, we searched for 
the presence of a genetic alteration in the set of gastric cancer cell lines. In this search, 
we found some point alterations, classified as SNP alterations. Although we found some 
base changes consistent with an missense alteration, these alterations have been 
reported in an high frequency in the 1000 Genomes Project Phase 1 (>1%) and in both 
alleles, witch lead us to infer that this alterations does not likely affect the protein function. 
These results can exclude the presence of mutations in the coding region, as a regulatory 
mechanism that could explain the down-regulation of Dies1 in this set of gastric cancer 
cell lines.  
Comparing the results obtained by Wang, et al. with ours results, the 2 mutations 
previously found in gastric cancer samples were not present in any of the 7 cell lines 
(130). Our results, although not revealing the mechanism of inactivation of Dies1 in gastric 
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cancer cell lines, allowed us to optimize the set of primers that were further used for 
characterize the possible presence of Dies1 mutations in our gastric cancer series. 
 
Traditionally, cancer was viewed as a set of diseases that are driven by accumulation of 
genetics alterations, although a growing body of evidences suggest that the disrupt of 
epigenetic regulatory mechanism are also involved in initiation and progression of cancer 
(136, 138). Aberrant DNA methylation was the first epigenetic mark to be associated with 
cancer and accumulating evidences reveal that DNA methylation plays an important role 
in oncogenesis (138, 139). DNA methylation refers to the addition of a methyl group at the 
5 position of the cytosine ring within CpG dinucleotides. The distribution of CpG 
dinucleotide in human genome are not uniform, instead they are concentrated in regions 
of large repetitive sequences, such centromeric repeats, and in short CpG-rich DNA areas 
called CpG islands, that frequently overlap with transcriptional start sites (140, 141). The 
hypermethylation of promoter region contributes for gene repression by inhibit the binding 
of activator transcription factors at their recognition sequence or recruits methyl binding 
proteins that recruit co-repressor molecules and leading silence transcription (132, 142). 
Aberrant methylation pattern, hyper or hypomethylation is present in promoter region of 
key players in gastric cancer leading to theirs expression regulation (139, 143).  
Given the close association with promoter hypermethylation and transcriptional silencing 
of tumour related genes, and the previous results in EMT/MET process, we studied the 
Dies1 promoter methylation pattern in our set of gastric cancer cell lines.  
The CpG island located at the transcription start site presented hypermethylation in AGS 
cell line and partially-methylation in GP202 cell line and in both cases this methylation 
status were negatively correlated with Dies1 expression. The remaining 5 cell lines 
studied did not present a methylation pattern in the promoter region, however 4 of them 
present a decrease of Dies1 expression.  
In order to confirm if methylation could be a possible regulatory mechanism of Dies1 
expression we studied the Dies1 promoter methylation status in 6 tumour cases that 
presented down-regulation of the expression this gene in our gastric cancer series. None 
of the 6 cases presented promoter CpG sites methylated, which led us to suggest that the 
regulation of this gene by promoter methylation is a rare event, and the decreased 
expression of Dies1 can be due to the effect of a different regulatory mechanism. The 
methylation profile of AGS and GP202 may be a possible mechanism for the expression 
down-regulation of this gene or be may unrelated with gene expression. (143, 144). 
Further studies it will be necessary to address if this mechanism can regulate the 
expression of Dies1 gene.  
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Considering the variety of mechanisms that can regulate gene expression, we studied 
gene expression regulation by microRNA (miR-125a), another mechanism already 
described for Dies1 protein expression regulation in mouse embryonic differentiation 
context (18). In previous works was reported that miR-125a directly targets Dies1 3’-UTR 
and regulates its expression. Also the overexpression of this miRNA recapitulates the 
effects of Dies1 suppression and blocks the mESC differentiation. In this study the authors 
also pointed that miR-125a controls Dies1 level through BMP4 signaling pathway, 
suggesting that exists a feedback loop between miR-125a, BMP4 signaling pathway and 
Dies1: BMP4 induces the transcription of miR-125a through phosphoSmad1 and down-
regulated the Dies1 expression that leads to the decrease the BMP4 signaling 
transduction (18). 
In our study the miR-125a-5p expression was increased relative to the normal counterpart 
in 3 cell lines, AGS, NCI N87 and MKN28, however only the AGS and MKN28 had a 
down-regulation of Dies1 gene. Also, KATO III cell line had a higher expression of miR-
125a-5p compared to Dies1 expression, but still lower than the expression of the normal 
gastric tissue.  
Once the miR-125a expression variation and its function as a regulatory mechanism for 
Dies1 expression has been related with BMP4 signaling pathway, we performed a search 
in the literature and found that only 4 (IPA220, AGS, GP202 and MKN28) of the 7 cell 
lines analyzed seem to have this signaling pathway functional. MKN45, KATO III and NCI 
N87 cell lines have been reported to not have or have a very low expression of key 
elements of BMP/Smad pathway, such Smad4, ALK6 or phospho-Smad1/5/8, suggesting 
that this pathway may not be functional (145, 146). The 4 cell lines with the BMP signaling 
pathway theoretically functional only the AGS and MKN28 presented a negative 
correlation between the miR-125a-5p and Dies1 expression, that may be associated with 
the regulatory function of this miRNA. The miR-125a-5p may regulate the Dies1 
expression in AGS and MKN28 cell lines by a feedback loop between miR-125a, BMP4 
signaling pathway and Dies1 as described by Parisi, et al. (18). However in KATO III cell 
line, the BMP/Smad signaling pathway appears to be inactive, and therefore miR-125a-5p 
is likely not be regulated by this pathway. These results represent an association in cell 
lines and further studies are need to confirm this as regulatory mechanism for Dies1 
expression in this setting. 
 
In summary of this part of the work, DNA methylation can be associated with Dies1 gene 
down-regulation in AGS and GP202 cell lines and miR-125a-5p may also be a regulatory 
mechanism for KATO III, AGS and MKN28 cell lines. However the non-existence of 
  71 
mutations lead us to exclude this genetic alteration as one of the possible mechanisms for 
Dies1 down-regulation. Also the mechanisms that lead to the low mRNA levels of Dies1 in 
MKN45, IPA220 and GP202 remain unclear. However others genetics and epigenetics 
mechanisms can explain the regulation of mRNA levels such: deletion of chromosomal 
regions bearing the Dies1 gene (loss of heterozygosity). The presence of heterozygosity 
in the SNP alteration in KATO III, NCI N87, GP202 and MKN28 cell lines reveal the 
presence of the 2 alleles in these cell lines, however in MKN45 and IPA220 the 
homozygous state at Dies1 SNPs does not allow us to evaluate the presence of the 2 
alleles. Alternative splicing is a post-transcriptional mechanism with a significant role in 
cancer and can also lead to no detection of the transcript of interest (147). Dies1 presents 
3 possible transcripts, 2 of them were not detected by the probe used in qRT-PCT, 
therefore alternative splicing may lead to a down-regulation of the Dies1 transcript. Other 
mechanisms can also induce a gene down-regulation, such as modification of 
nucleosomal histones, repression of transcription by repressor transcription factors or 
even regulation by another miRNA.   
 
The evaluation of Dies1 expression in our gastric cancer series revealed a different 
expression of this gene compared with the previous tumour cases on preliminary results. 
In our series Dies1 displayed an increase expression in tumour samples compared with 
the normal pair, also, this difference was present in the intestinal type but not in diffuse 
histotype.  
These results were not consistent with the previous series and the cell line results. In 
addiction to the fact that were 2 distinct series of gastric cancer, we used normal-tumour 
paired samples that allow us to eliminate the inter-personal variability, whereas the 
previous series used a pool of normal samples, not paired with the tumour samples. 
These difference can influence and lead to a different result between the 2 series. Besides 
this difference, we cannot exclude the fact that in some cases we used the normal 
adjacent mucosa as normal sample that, besides its had a non-tumorous morphology, it 
can have already some alterations involved in carcinogenesis that can dilute the 
differences between the normal and tumour sample.  
Gastric cancer is a heterogeneous tumour that frequently present on tumour 
microenvironment (TME) a high inflammatory cell infiltration. Some studies reported that 
Dies1 (termed VISTA) was highly expressed on myeloid cells, such macrophages, 
monocytes and dendritic cells, and expressed at lower levels in CD4+ and CD8+ T-cells (2, 
31, 148). Recent reports disclose the function of Dies1 in cell immunity: this gene 
expressed on antigen-presenting cells (APCs) directly supress CD4+ and CD8+ T-cell 
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proliferation, cytokine production, T-cell activation and T-cell-mediated immune responses 
(2, 31, 149). Le Mercier and colleagues found a high expression of Dies1 protein in 
myeloid cells population on TME in murine cancer models, such bladder and melanoma 
tumour models (31, 149). Also in this study the authors reported that the treatment with a 
mAb against Dies1 in melanoma murine cancer model and in the transplantable tumour 
model alter the suppressive cellular signature of the TME, by reducing the tumour-
infiltrating monocytic myeloid-derived suppressor cells while increasing the frequency of 
infiltrating effector T cells. This was accompanied by the enhanced proliferation, activation 
and effector function of tumour-infiltrating T cells, which likely contribute to impair tumour 
growth (31, 149). Also the effects of Dies1 mAb treatment facilitate the establishment of 
an immune-stimulatory TME, which lead to enhance antitumor immunity (31, 149).  
Taking these studies in consideration, we cannot exclude the possibility that the over-
expression of Dies1 gene in some tumour samples in our gastric cancer series can be due 
the expression of this gene in the inflammatory cells. To exclude this cell “contamination” 
and study only the tumour cells in further studies, we must do a micro-dissection of 
tumour cells, or perform a protein characterization that can unclear the source of Dies1 
expression.  
In present study we already tried to perform the protein staining for better characterize the 
role of Dies1 in gastric cancer. However the antibody instability, and the heterogeneous 
staining did not permit us to characterized the Dies1 protein in normal mucosa and in 
gastric cancer samples. The protein characterization in mouse tissue seems to have 
better results, this could be due the controlled technical procedure that permitted 
improved the antigen epitope conservation (150). Besides the controlled histological 
technique the antibody maintained an instable staining with different intensity in the same 
tissue and using the same protocol. This seems also be a recurrent problem, once the 
studies that performed a Dies1 protein characterization had to use an epitope tagging 
technique or generated their own antibodies, reflecting the lack of specific antibodies 
commercially available (1, 2, 5). In order to study this protein in the tissue context, we 
must produce our own antibody or overexpress the protein bound to a tag.   
 
The results of a preliminary study performed in our group revealed that Dies1 expression 
varies along the EMT/MET process in an in vitro model, and seemed to follow the 
epithelial markers. This result prompted us to study the association of Dies1 expression in 
gastric cancer with an epithelial and mesenchymal marker, which are often associated 
with the EMT process. The epithelial marker chosen for us to perform this study was the 
E-cadherin (CDH1), that besides being a classical marker in EMT process in many in vitro 
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studies, the alteration of this protein in gastric cancer is associated with loss of cell 
differentiation, tumour development and invasion (111)  
N-cadherin (CDH2) is a protein often associated with EMT process and is known as a 
mesenchymal cadherin. In epithelial cancers N-cadherin is frequently studied as a 
mesenchymal marker and in some gastric cancer studies has been associated with 
unfavourable prognosis, and suggest playing a role as a pro-migratory cadherin (123, 
151). These 2 cadherins are often described in literature to have a negative correlation 
and to be associated with cell motility and tumour invasion. The inverse correlation of 
CDH1 and CDH2 was also present in the mesenchymal type of the molecular gastric 
cancer classification (85).  
In our gastric cancer series the overall expression of CDH2 present a similar expression 
between normal and tumour samples, also there was no difference in CDH2 expression in 
the different histological type. However, when we analysed the gene expression 
normalized for the normal counterpart we can verify that from 7 cases with an 
overexpression of CDH2, 5 of them belongs to the diffuse type. The association of 
increased N-cadherin (CDH2) expression and the diffuse histotype was also obtained in 
previous studies (85, 123, 152). Besides these results, there was no relation with the 
increased expression of CDH2 and a decreased expression of CDH1 in our gastric cancer 
series, what excludes the presence of a negative relation between these 2 markers at 
mRNA level in our gastric cancer series. 
The analyses of protein expression could give us a better relation between the N-cadherin 
and E-cadherin expression, however the staining of N-cadherin in our gastric cancer 
series was negative in all cases, including the cases with an overexpression at mRNA 
level. This fact was also observed in another study that compared the mRNA expression 
and the N-cadherin protein levels, and only one case resulted in immunodetection (152). 
Posttranslactional modifications or other inactivation mechanism, such proteolytic 
cleavage, can create alterations in protein conformation and impossibility the antibody 
binding. These alterations must be limited to the tumour cells, since the positive internal 
control (ganglion cells) had a specific positive staining. Also the low levels of N-cadherin 
protein in tumour cells may not be sufficient and be below the sensitivity limits of antibody 
detection or even the mRNA may not be translated into protein, which can explain the lack 
of detection of this protein. 
Our results also lead us to conclude that N-cadherin levels do not vary significantly in our 
gastric cancer series. Others markers, as example of vimentin, fibronectin, S100A4, 
phosphor-SRC and Snail1 must be further studied to better characterize our tumour series 
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about the presence of mesenchymal characteristics associated with EMT process and 
correlate with Dies1 expression. 
Contrarily to CDH2, Dies1 expression seems to have the same trend than the epithelial 
marker, CDH1. Both genes had an increase expression between normal and tumour 
samples, this increase was also significative in intestinal type but not in diffuse type. In the 
analyses of the expression of this 2 genes when normalized for the normal pair, 74% 
(14/19) of the cases had a concordant expression of CDH1 and Dies1 (the 2 genes had a 
higher, lower or the same expression compared to the normal pair).  
All these results allowed us to demonstrate that Dies1 and CDH1 expression seem to 
have an association in our gastric cancer series. Similar to preliminary results of 
EMT/MET model, in gastric cancer Dies1 seems to accompany the epithelial marker 
CDH1. However this results concerns only mRNA levels and Dies1 expression was only 
associated to one epithelial marker that given us a lack of information about its 
association to epithelial characteristics.  
The detection of E-cadherin protein provided us with better information about the 
presence and the correct function of this protein, once the mRNA levels did not 
correspond to protein levels. E-cadherin may suffer post-transcriptional alterations that 
lead to a loss of protein expression or loss of normal pattern, and therefore affect the 
correct function of the protein. This is clear in our gastric cancer series for example, 4 
cases with an increased expression of CDH1 at mRNA level do not have expression of E-
cadherin protein. Other cases had an increased expression of CDH1 compared to the 
normal pair and had an abnormal protein expression (incomplete staining at membrane, 
cytoplasmic staining, dotted pattern). These results reflect the importance of the protein 
analyses to characterize the role of Dies1 in gastric cancer and its association with the 
epithelial or mesenchymal marker. Further studies need to be performed to associate E-
cadherin and Dies1 at protein level, and associate Dies1 with others epithelial markers.  
 
The following scheme represents a resume of the present study (figure 21).  
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Figure 21 – Schematic representation of Dies1 study. A. Quantification of Dies1 mRNA levels using qRT-
PCR; B. IHC techniques used for characterize Dies1 protein, however due technical problems this objective 
was not successful accomplished. 1., 2. and 3. Different regulatory mechanisms for Dies1 expression studied 
in present work. Black lines in DNA sequence represent the alterations found in gene sequence. E, exon; 
TSS, transcription start site; TM, transmembrane domain.  
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CONCLUSION 
 
In present work we studied the expression of Dies1, a gene involved in ESC 
differentiation, and the possible regulatory mechanisms of this gene in gastric cancer.  
This gene had a lower expression in almost all gastric cancer cell lines studied compared 
with the normal counterpart, this results was consistent with the previous one achieved in 
a series of gastric cancer and allows us to study a possible regulatory mechanism that 
lead to a down-regulation of Dies1 expression. 
The analysis of 3 possible regulatory mechanisms, in particular, gene sequence 
alterations, promoter methylation and regulation by miR-125a-5p, lead us to suggest that 
the last 2 mechanism seem to regulate Dies1 gene expression. Promoter methylation was 
the possible mechanism controlling the Dies1 expression in 2/7 gastric cancer cell lines 
but it was not found in primary gastric cancer samples with a down-regulation of Dies1 
mRNA. Therefore Dies1 promoter methylation is likely a rare regulatory mechanism for 
Dies1 expression in gastric cancer. The expression regulation by miR-125a-5p seems to 
be present in 3/7 cell lines, but this mechanism was not explored in primary tumour 
samples. Overall, we believe that others mechanism may be involved in Dies1 gene 
expression regulation in gastric cancer. 
The second aim of this study revealed that in our gastric cancer series, Dies1 expression 
had an apparent association with the expression of the epithelial marker, CDH1, which 
may indicate Dies1 as a gene associated with an epithelial differentiation. 
 
Our study was a first reporting in analysis on the role of Dies1 in gastric cancer, and 
suggests that Dies1 is differentially expressed in gastric cancer and that different 
mechanisms may explain its expression modulation, namely promoter methylation and 
expression of miR-125a-5p. The correlation observed between Dies1 and CDH1 
expression suggests an association of Dies1 with epithelial differentiation. 
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CHAPTER 7 
FUTURE PERSPECTIVES 
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FUTURE PERSPECTIVES 
 
The work development in this thesis was the first approach for study the role of Dies1 in 
gastric cancer. Many issues and unanswered questions still need to be clarified and future 
works are necessary to better understand the role of this gene in gastric cancer such: 
 
- Expression analysis of Dies1 in a larger gastric cancer series. 
 
- Microdissection of tumour cells and analysis the Dies1 expression to exclude the 
possibility that the increased of its expression was due to a “contamination” by the 
inflammatory infiltrate in TME. To exclude this possibility and to characterize the 
expression of Dies1 protein in normal gastric mucosa and in gastric cancer an IHC 
technique with an optimized antibody must be accomplish.  
 
- Characterize the expression of Dies1 protein concomitantly with the EMT markers, such 
vimentin, fibronectin, phospho-Src, Snail, Twist, and others to study the association of this 
protein expression with the EMT process in gastric cancer. 
 
- Study the association of Dies1 mRNA or protein expression with the BMP signalling 
pathway. In ESC differentiation Dies1 function as a co-receptor of BMP signalling 
pathway, and its down-regulation lead to a decrease of this signalling function, also the 
regulation of Dies1 by miR-125a-5p seems to be related with this signalling pathway. In 
gastric cancer Dies1 can also be involved in BMP pathway, so, to clarify this association, 
and study the association with miR-125a-5p regulation and BMP pathway further studies 
must be done. 
 
- Perform further studies to prove that the hypermethylation and miR-125a-5p are 
regulatory mechanisms of Dies1 expression in gastric cancer. Examples of studies that 
can be performed are: treatment with 5-aza-2-deoxycytidine to prove that promoter 
methylation is a regulatory mechanism; analysis of the expression of miR-125a-5p in the 
gastric cancer series; blockade of the miR-125a-5p and measurement of the expression of 
Dies1.  
 
Further studies are necessary to clarify the unanswered questions raised with the present 
study. 
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